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SUMMARY 
 
The study describes: 
 
 The synthesis of a racemic mixture of Compound A (2-(4-acetoxyphenyl)-2-chloro-N-
methylethylammonium chloride), a synthetic analogue of the active compound isolated 
from the African shrub, Salsola tuberculataformis Botschantzev. 
 
 The development of a strategy to separate the R- and S-enantiomers of Compound A. 
 
 The isolation and purification of a highly purified substrate-free cytochrome P450 
11β-hydroxylase (CYP11B1) from ovine adrenals. 
 
 The isolation of a partially purified mixture of the mitochondrial electron transport chain, 
adrenodoxin reductase and adrenodoxin from ovine adrenals. 
 
 The investigation into the mechanism of action of the R- and S-enantiomers of 
Compound A on the spectroscopic properties of substrate-free CYP11B1. 
 
 The investigation into the influence of the R- and S-enantiomers of Compound A on the 
mitochondrial electron transport chain by using cytochrome c as an electron acceptor. 
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OPSOMMING 
Hierdie studie beskryf: 
 
 Die sintese van ‘n rasemiese mengsel van Verbinding A (2-(4-asetoksifeniel)-2-chloro-
N-metielammoniumchloried), ‘n sintetiese analoog van die aktiewe molecule wat in die 
Suider-Afrikaanse plant, Salsola tuberculataformis Botschantzev. 
 
 Die ontwikkeling van 'n strategie om van die R- en S-enantiomere van Verbinding A te 
skei. 
 
 Die isolering en suiwering van ‘n hoogs gesuiwerde, substraat-vrye sitochroom P450 
11β-hidroksilase (CYP11B1) uit skaap-byniere. 
 
 Die isolering van ‘n gedeeltelike gesuiwerde mengsel van die mitokondriale 
elektrontransportketting, adrenodoksienreduktase en adrenodoksien uit skaapbyniere.  
 
 ‘n Ondersoek na die meganisme van werking van die R- en S-enantiomere van 
Verbinding A op die spektroskopiese eienskappe van ‘n gesuiwerde substraat-vrye 
CYP11B1. 
 
 ‘n Ondersoek na die invloed van die R- en S-enantiomere van Verbinding A op die 
mitokondriale elektrontransportketting met behulp van sitochroom c as 'n 
elektronakseptor. 
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CHAPTER 1 
General Introduction 
 
Salsola tuberculatisformis Botschantzev (Salsola tuberculata) is a robust and hardy shrub 
native to the arid regions of the Namibian desert. During periods of low rainfall, this drought-
resistant shrub is a highly valued source of nutrition for livestock (1). In 1906, Ploss described 
the utilization of an aqueous extract of plants belonging to the genus Salsola (Family: 
Chenopodiaceae) as an oral contraceptive for Algerian women (2). In addition, Sir Laurens 
Jan van der Post, an authority on Bushmen folklore and culture, also noted the utilization of 
the aqueous extracts of this genus as an oral contraceptive by the local Bushmen women (3, 
4). 
The biological effects of this African shrub were first brought to scientists’ attention in 1961, 
when De Lange observed a syndrome of prolonged gestation in Karakul sheep, which 
occurred during periods of severe drought in the Keetmanshoop region of southern Namibia 
(5). This syndrome, known as “Grootlamsiekte”, prolonged the normal gestation period of 
Karakul sheep from ± 149 days to 213 days, which affected the vigour, size and pelts of the 
new born. At birth, the Karakul lambs have high quality, soft, strong and tightly-curled black 
wool, which is used to make a variety of soft, warm and elegant garments for international 
export. However, when the lambs grow older the tightly curled wool becomes straight, changes 
to a greyish colour and loses its silky appearance. Lambs are therefore slaughtered within 24 
hours after birth to preserve the high-quality pelts (6). It is thus clear that “Grootlamsiekte” had 
detrimental financial implications for the world renowned Karakul industry, as the pelts of the 
new born were considered worthless for international trade.  
The heavy losses that the Karakul farmers experienced initiated an investigation into 
identifying this syndrome and eliminating the cause. In 1969, Basson et al, discovered that 
ingestion of the hardy African shrub by the Karakul ewes was the agent responsible for this 
condition (6). The logical response to Basson’s discovery was to isolate and characterize the 
active compound(s) in the shrub. The highest priority was placed on developing a reliable 
bio-assay in order to investigate the biological mechanism of action of the active compound(s) 
in Salsola tuberculata. This was an extremely challenging task, as the hormonal changes in 
both the ewe and foetus responsible for maintenance of pregnancy are influenced by several 
factors (7–9). These factors are divided into four main groups, namely: maternal, foetal, 
genetic and environmental. Examples corresponding to each group include: the age of the 
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lamb, hormonal changes caused by pituitary and adrenal function, the genotype of the foetus, 
the maternal gestational diet, and lifestyle factors. Therefore, when considering the length of 
gestation and the various factors that influence the maintenance of pregnancy in ewes, it 
became apparent that using the Karakul sheep as experimental animals would not be 
appropriate for screening tests. Thus, sexually mature laboratory rats were considered a more 
appropriate experimental model, given their significantly shorter gestation period of 21-23 
days. These test animals posed similar problems to the sheep, as the prenatal development 
of the foetus is interdependent on the numerous factors previously mentioned. Nevertheless, 
when the natural plant extract was fed to pregnant rats, screening tests revealed a rise in 
foetal resorption during early pregnancy, and foetal death during later stages of pregnancy. 
However, when virgin female rats were fed with various concentrations of the dry plant extract, 
they noticed an inhibitory effect in their oestrus cycle (6, 7, 9). The results obtained during this 
investigation are shown in Figure 1. 
The results indicated that Salsola tuberculata possibly contained active compound(s) 
responsible for both the observed extended gestation period in Karakul ewes and the 
contraceptive effect in rats (6). These findings considered together with the notion that the 
Algerian and Bushmen women used the same plant for its contraceptive purposes motivated 
the development of a bio-assay which focused mainly on Salsola tuberculata’s contraceptive 
properties (2, 3, 6, 7). To perform this bio-assay in virgin rats, researchers administered the 
Figure 1. Inhibitory effect on the estrus cycle after feeding rats with Salsola tuberculata. Lucerne meal was used 
as a control. Redrawn from (7), original image from (6). 
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plant extract and collected and analysed daily vaginal smears using appropriate staining 
techniques. In combination with this bio-assay, standard methanol extraction- and 
chromatographic procedures were used to extract the contraceptive agent from the plant. 
However, the methanol extract was highly labile and displayed rapid autocatalytic 
decomposition behaviour under standard laboratory conditions (6). Nevertheless, Van der 
Merwe et al. succeeded in isolating the contraceptive agents by treating the extract with the 
derivatizing reagent, trimethylammonium acetyl hydrazide chloride (Girard-T reagent), which 
is known to remove ketones and aldehydes (4, 9, 10). Subsequently, the reaction derivatives 
were subjected to standard solvent partitioning and, under acidic conditions, the derivatives 
decomposed into three organic compounds (Figure 2). These compounds were identified by 
electron ionization-mass spectrometry (EI-MS) and proton-nuclear magnetic resonance 
(1H-NMR) as (A) 4-hydroxy-acetophenone (Figure 2 A), (B) 4-hydroxy-3-methoxy-
acetophenone (Figure 2 B) and (C) 4-hydroxy-benzaldehyde (Figure 2 C). Biological studies 
revealed that the ketones (A and B) were to some extent biologically active in the rats, 
whereas the aldehyde (C) was entirely inactive. However, further investigations revealed that 
neither the ketones nor the aldehyde accounted for the contraceptive effects of the shrub. 
Unfortunately, the extracted compounds were sensitive to light, air, pH and heat and thus 
rapidly deteriorated under standard laboratory conditions (4, 9).  
 
 
 
 
Researchers were compelled to re-evaluate their extraction method and, due to the labile 
nature of the active compounds, replaced the time-consuming rat bio-assay with a more 
reliable, rapid, and sensitive method (9). The highly labile nature of the extracted bio-active 
compounds made the development of a new assay and extraction method a daunting task. 
Nevertheless, it appeared that two seemingly unrelated publications of Williamson and 
O’Donnell (1969) and Liggins and Fairclough (1973) offered new insights into resolving the 
problem (11, 12).  
Figure 2. Chemical structures of the compounds found in the Salsola tuberculata extract.  Biologically active 
ketone derivatives namely, A, 4-hydroxy-acetophenone and B, 4-hydroxy-3-methoxy-acetophenone, respectively 
and the biologically inactive aldehyde derivative, C, 4-hydroxy-benzaldehyde. Redrawn from (4). 
A. B. C. 
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 The first publication revealed that the synthetic agent, metyrapone (Figure 3) 
(2-methyl-1,2-di-pyridin-3-yl-propan-1-one) inhibited the binding of the substrate, 
deoxycorticosterone (DOC) and deoxycortisol, to the terminal enzyme in the 
glucocorticoid biosynthesis pathway, cytochrome P450 11β-hydroxylase (CYP11B1), 
resulting in the reduced production of corticosterone (CORT) and cortisol, respectively 
(11). 
 The second publication discovered that a rise in the level of cortisol in foetal plasma 
triggers the onset of parturition in sheep (12).  
The combined knowledge of the two publications led to the assumption that the active 
compound(s) of the shrub interfered with adrenal steroidogenesis and, more specifically, with 
the terminal reaction in the glucocorticoid biosynthesis pathway in both animals (7). It was, 
therefore, hypothesised that the active compound(s) in the shrub inhibited CYP11B1 and 
caused perturbations in cortisol production (7, 13, 14). This assumption was verified 
experimentally by feeding sexually mature female rats with metyrapone. Not only did 
metyrapone share structural similarities with the biologically active ketones (Figure 3), but 
metyrapone also mimicked the physiological consequences of the shrub (15). 
 
 
 
 
The implications of these discoveries led to the development of a new bio-assay, which was 
based on the unique spectroscopic and catalytic properties of the adrenal steroidogenic 
enzyme, CYP11B1 (7, 14, 15). With the aid of difference spectroscopy, the unique spectral 
properties of CYP11B1 can be used to:  
 Measure the interference of a test compound (inhibitor) on the binding of the natural 
substrate (DOC) with the enzyme (CYP11B1). 
 Directly measure the interaction of a test compound (inhibitor) with the enzyme without 
the presence of natural substrate. 
The mode by which a test compound (inhibitor) influences the spectroscopic properties of 
CYP11B1 can be used to understand its mechanism of action on a micro-scale (7, 16–18). 
Figure 3. Chemical structure of metyrapone, a synthetic inhibitor of CYP11B1. Redrawn from (4). 
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Since adrenal steroid metabolism and the spectroscopic properties of CYP11B1 play such an 
important role in this study, a detailed overview of adrenal steroid metabolism and 
cytochrome P450 enzymes will therefore be provided in Chapter 2. 
The new bio-assays were successfully applied to a new screening method, which served as 
a more rapid and sensitive approach to identifying active compounds from Salsola tuberculata 
(7, 15, 18). Armed with a new screening method and high performance liquid chromatography 
(HPLC), Swart and Swart successfully isolated two biologically active HPLC fractions from the 
shrub, namely S1 and S2 (7, 18). Due to the labile nature of both fractions, precautionary 
steps needed to be taken to preserve their activity. The fractions were therefore shielded from 
light and oxidation, and stored in an acidic environment. Even after these steps were taken, 
only the S2 fraction remained active in biological studies (7, 18, 19). Despite these advances, 
the highly labile nature of the S2 fraction severely hindered the investigation into its chemical 
structure. Additionally, the lack of modern nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) facilities, and the use of gas chromatography-mass spectrometry (GC-MS), 
prevented the direct elucidation of the structure at the time. However, by acetylating the S2 
fractions and by using analytical techniques, such as gas chromatography (GC) and fast atom 
bombardment mass spectrometry (FAB-MS), researchers confirmed that the acetylated S2 
was the precursor of both synephrine (Figure 4 A) and a highly reactive aziridine (Az) (Figure 
4 B) (20–23).  
 
 
   
 
 
 
 
Az, also known as ethylenimines, are highly reactive compounds, characterized by a 
three-membered ring structure, consisting of one amine group and two methylene bridges. 
The high lability and reactive characteristics of most aziridines are attributed to the high level 
of strain in the three membered ring structure. Therefore, to decrease the strain and increase 
the stability of the compound, Az readily reacts with a number of nucleophiles (which tend to 
be good leaving groups e.g. chlorine ion (Cl-), to form ring-opened products (4, 24, 25). 
  
Figure 4. Chemical structure of (A) synephrine and (B) aziridine, the chemical precursors of the S2 fraction. 
Redrawn from (4). 
B. 
A. 
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It was therefore hypothesized that the labile nature of the active compound(s) in the S2 fraction 
was attributed to the Az moiety (21–23). In an attempt to obtain a more stable derivative of the 
S2 fraction, an Az precursor was synthesized, known as Compound A (2-(4-acetoxyphenyl)-2-
chloro-N-methylethylammonium chloride) (Figure 5) (24). Compound A (CpDA) served as an 
appropriate model for both in vivo and in vitro studies, as it mimicked the properties of its 
natural counterpart and the S2 fraction (26, 27). Additionally, it could be stabilised by 
steroid-binding globulins in plasma, thus enhancing its biological activity in vivo (28, 29). 
 
 
 
 
 
 
To date, evidence has shown that CpDA acts as a non-steroidal multi-target androgen 
receptor (AR) and glucocorticoid receptor (GR) modulator (30). In vivo studies have revealed 
that CpDA has anti-cancer properties by repressing AR function (31–33). Similarly, numerous 
in vitro studies have shown that like synthetic glucocorticoids, CpDA has anti-inflammatory 
and immunosuppressive properties (34–43). CpDA promotes the translocation of the GR into 
the nucleus, however, it prevents GR dimerization and consequently inhibits the GR 
transactivation pathway. Instead CpDA binds as a homodimer to the glucocorticoid response 
element and promotes the GR transrepression pathway. It is well known that the adverse 
effects associated with the chronic use of glucocorticoids are mediated by GR transactivation. 
Since CpDA diverts from GR transactivation, it has the unique ability to retain the 
anti-inflammatory and immunosuppressive potential of glucocorticoids, but with reduced side 
effects (30, 44–46). However, the use of CpDA has limitations, as it has a narrow range (±1-
15 mg/mL) in which it can elicit a therapeutic response. High concentrations of CpDA became 
intrinsically toxic to the cells, whereas low concentrations had a limited anti-inflammatory 
response. Moreover, in contrast to glucocorticoids, a 10-fold increase in the concentration of 
CpDA is needed to induce the same anti-inflammatory effect (30). Because the unique 
pharmacological properties of CpDA can be applied in future clinical treatment of diseases 
associated with the AR/GR or both receptors, it would be beneficial to develop a method 
wherein the therapeutic window of CpDA can be improved. 
  
Figure 5. Chemical structure of CpDA, the synthetic analogue of the S2 fraction. Redrawn from (4). 
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CpDA is, however, a chiral compound consisting of a 1:1 ratio of the R- and S-enantiomers 
(24, 30). It is important to note that all biological and comparative studies on CpDA, both 
in vitro and in vivo, have been performed using a racemic mixture of the compound (30). 
Although enantiomers have the same chemical composition, it is well-known that, in a 
biological environment, most single enantiomers have their own pharmacological profile and 
that the enantiomers should be classified as two distinct compounds, unless proven otherwise. 
Therefore, one enantiomer may be pharmacologically active, whereas the other enantiomer 
may be inactive, and even result in severe side effects. Consequently, it is important to 
separate the R- and S-enantiomers of CpDA, as the single enantiomeric form could potentially 
lead to a simpler and improved pharmacological profile, provide a greater understanding of 
the biological nature of each enantiomer, and similarly offer an alternative means of increasing 
its therapeutic range. A powerful tool that could aid in increasing the therapeutic window of 
CpDA is known as chiral resolution, which involves the separation of the R- and S-enantiomers 
of a racemic compound (47–52). 
Aim of the study 
The aim of this study was to separate the R- and S-enantiomers of CpDA and to determine 
the biological activity of each enantiomer. The biological activities of the single enantiomers 
were investigated by using the spectroscopic properties of mitochondrial CYP11B1 from ovine 
adrenals. In addition, the influence of CpDA was also tested on the mitochondrial electron 
transport system from ovine adrenals by using cytochrome c as an electron acceptor. As part 
of a comparative study, the effects of the R- and S-enantiomers of CpDA was compared to 
the racemic mixture of CpDA. The hypothesis of this study is that either the R- or S-
enantiomers of CpDA may yield a more effective inhibitory profile. 
The objectives addressed in this study can be summarized as follows: 
1. Synthesize a racemic mixture of CpDA. 
2. Develop a method to separate the R- and S-enantiomers of CpDA. 
3. Screen for biological activity of the R- and S-enantiomers of CpDA and the racemic 
mixture of CpDA by using the spectroscopic properties of partially purified CYP11B1 
from ovine adrenals. 
4. Isolate and purify CYP11B1 from ovine adrenals. 
5. Investigate the mechanism of action of the R- and S-enantiomers of CpDA by using 
the spectroscopic properties of purified CYP11B1. 
6. Isolate the mitochondrial electron transport chain, adrenodoxin (ADX) and adrenodoxin 
reductase (ADXR) from ovine adrenals. 
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7. Investigate whether the R- and S-enantiomers of CpDA influence the electron transport 
system of CYP11B1. 
The approach to this study is reported in four chapters as outlined below: 
Chapter 2 – Adrenal steroidogenesis and cytochrome P450 enzymes 
In Chapter 2 of this thesis, a literature review of adrenal steroidogenesis and cytochrome P450 
enzymes is provided. This chapter focuses on the structure and function of the adrenal gland, 
the biosynthesis of adrenal steroid hormones, and the regulation of enzymes involved in the 
glucocorticoid biosynthesis pathway. Furthermore, a comprehensive overview of cytochrome 
P450 enzymes is provided including the discovery, the unique active site, the mechanism of 
action of the P450-dependent hydroxylation reactions, the electron transport system in the 
hydroxylation reaction and finally, the unique spectral and catalytic properties of the 
P450-dependent enzymes. 
Chapter 3 – Synthesis of a racemic mixture of CpDA and the chiral resolution of the R- and 
S-enantiomers of CpDA  
This chapter reports on the synthesis and chiral resolution of the R- and S-enantiomers of 
CpDA. Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-ToF MS) 
was used for the accurate mass determination of CpDA and the R- and S-enantiomers of 
CpDA. Additionally, NMR spectroscopy were employed for direct structure elucidation. The 
spectroscopic properties of partially purified CYP11B1 was used to screen for biological 
activity of CpDA and the R- and S-enantiomers. 
Chapter 4 – The interaction of CpDA and its enantiomers with purified ovine adrenal cytochrome 
P450 11β-hydroxylase and adrenal mitochondrial electron transport 
In Chapter 4, the isolation and purification of CYP11B1, and the isolation of ADX and ADXR 
are described. CYP11B1, ADX and ADXR were isolated from a P450-enriched mitochondrial 
powder prepared from ovine adrenals. The purification of CYP11B1 was achieved by using 
hydrophobic interaction liquid (HIC) chromatography on a Phenyl-Sepharose column. The 
purity of CYP11B1 and isolated ADX/ADXR solution was assessed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. The biochemical 
mechanism of action of the R- and S-enantiomers were determined by using the spectroscopic 
properties of purified CYP11B1. The influence of single enantiomers was also tested on the 
mitochondrial electron transport chain by using cytochrome c as an electron acceptor. The 
results obtained during the spectroscopic assays with the enzyme and electron transport 
system were compared to the racemic mixture of CpDA. 
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Chapter 5 - General discussion 
Chapter 5 presents a thorough discussion of the results described in Chapter 3 and Chapter 4, 
and highlights the main conclusions which can be drawn from the study. This chapter 
concludes with the significance of this research study and a proposal of future work. 
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CHAPTER 2 
Adrenal steroidogenesis and cytochrome P450 enzymes 
 
2.1 Introduction 
The adrenal cortex, located within the adrenal glands, produces the adrenal steroid hormones 
which regulate crucial physiological and developmental processes throughout the body (53). 
These steroid hormones are all derived from a common precursor, cholesterol, with the aid of 
an intricate network of mono-oxygenase reactions that are catalysed by different cytochrome 
P450  enzymes (53, 54). The adrenal steroid hormones can be divided into three distinct 
classes, namely: mineralocorticoids, glucocorticoids and adrenal androgens (53–55). Each 
class has its own essential role in the body. Abnormalities within the expression levels and/or 
activity of steroidogenic enzymes result in perturbations in the delicate steroid hormone 
balance, causing abnormal physiological responses (7, 18, 54, 56). The occurrence of 
prolonged gestation in sheep and the contraceptive action in rats, discussed in Chapter 1, can 
be understood in terms of the active compounds in the shrub directly affecting the activity of 
CYP11B1, resulting in an inhibition of glucocorticoid production. 
The following subdivision will be devoted to understanding adrenal steroid metabolism and 
the intricate role of cytochrome P450 enzymes in the adrenal cortex. 
2.2 The anatomy of the adrenal gland 
The adrenals are two small bilateral encapsulated endocrine glands situated above each 
kidney. These glands consist of two distinct types of tissues, the adrenal cortex and the 
adrenal medulla, which are structurally, functionally and biochemically distinct from one 
another (Figure 6) (7, 18, 54).  
  
Stellenbosch University  https://scholar.sun.ac.za
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 6, the adrenal is enclosed by a robust layer of connective tissue, known 
as the capsule (57). Beneath the capsule is the adrenal cortex, which consists of three 
morphologically distinct layers, namely: the outermost region - the zone glomerulosa; the 
middle region - the zona fasciculata; and the innermost region - the zona reticularis. The 
adrenal medulla is found in the centre of the adrenal and is encircled by the zona reticularis 
(57, 58). Each zone of the adrenal cortex produces a specific class of adrenal steroid hormone 
by following a range of enzymatic reactions unique to its production. The medulla produces 
the catecholamines, adrenaline and noradrenaline, which are responsible for the body’s fight-
and-flight response (54, 55, 58). The zona glomerulosa (outermost region) is responsible for 
the secretion of the mineralocorticoid aldosterone (ALDO), which controls the water and 
electrolyte balance in the body (54, 59). The zona fasciculata (middle region), which is 
continuous with the zona glomerulosa, is responsible for the biosynthesis and secretion of the 
glucocorticoids cortisol and CORT. The hormones released from this zona have numerous 
functions which aid in fat and protein metabolism, stress tolerance, and the suppression of 
inflammatory and immune responses. The innermost region of the adrenal cortex is known as 
the zona reticularis and is responsible for the biosynthesis of the adrenal androgen precursors, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEAS) and 
androstenedione (A4) (54, 55, 59). 
 
 
Figure 6. Cross-sectional schematic of the adrenal gland, with the capsule encapsulating the cortex and the 
medulla. The adrenal cortex is divided into three distinct layers, namely the zona glomerulosa, zona fasciculata 
and zona reticularis. Each of these layers produce the mineralocorticoids, glucocorticoids and adrenal androgen 
precursors, respectively. Reproduced from (57). 
Stellenbosch University  https://scholar.sun.ac.za
 
 
12 
 
2.3 Cholesterol, the precursor of adrenal steroid hormones 
All adrenal steroid hormones are fat soluble, organic compounds with a characteristic 
cyclopentanoperhydrophenanthrene ring structure derived from a common precursor, 
cholesterol (Figure 7) (7, 18, 53, 54).  
  
 
 
 
 
Although adrenal steroid metabolism is regulated by tissue specific trophic hormones; a 
constant supply of cholesterol is essential for the optimum production of adrenal steroids (53, 
54, 60). There are three ways in which cholesterol can be utilized in steroidogenic cells: 
Cholesterol can be biosynthesized de novo from acetate in the endoplasmic reticulum (ER) 
through a series of complex enzymatic reactions Figure 8 (1). The cholesterol ester stored in 
the lipid droplet can be released as free cholesterol by a hydrolysis reaction Figure 8 (2) or 
cholesterol can be derived from two circulating lipoproteins in plasma namely, the low density 
lipoprotein (LDL) and the high density lipoproteins (HDL) Figure 8 (3) (53, 60). Although the 
first two mechanisms can potentially provide enough cholesterol to support adrenal 
steroidogenesis, evidence suggests that steroidogenic tissue and cells primarily utilize 
cholesterol from circulating lipoproteins for steroid hormone production (60). The utilization of 
LDL or HDL as the primary source of cholesterol is, however, species-dependent. Humans, 
cattle and pigs primarily use plasma LDL to obtain an adequate amount of cholesterol for 
steroid production, whereas rodents meet their cholesterol requirements for steroidogenesis 
by utilizing plasma HDL (53, 60).  
The HDL cholesterol esters can enter the steroidogenic cell via the scavenger receptor class 
B type I (SR-B1) receptor-mediated pathway, which allows the direct transfer of HDL 
cholesterol esters into the cytoplasm. Once HDL cholesterol ester enters the cell, it is stored 
in a lipid droplet. However, when the demand for free cholesterol is high, the 
hormone-sensitive lipase (HSL) enzyme will convert the HDL cholesterol ester into free 
cholesterol (53, 54). 
Figure 7. Chemical structure of cholesterol, representing the backbone of all the steroid hormones. Redrawn 
from (60). 
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The uptake of LDL cholesterol ester from plasma into the cytoplasm of steroidogenic cells is 
mediated by the LDL-receptor through a process of receptor-mediated endocytosis (53, 54). 
The endosome, containing the LDL cholesterol ester, fuses with lysosomes (membrane-bound 
organelles that contains degradative enzymes) which hydrolyses the LDL cholesterol ester to 
release free cholesterol (53, 60). The steroidogenic acute regulatory protein (StAR) mediates 
the transfer of free cholesterol from the outer mitochondrial membrane (OMM) to the inner 
mitochondrial membrane (IMM). Only free cholesterol is transported into the adrenal IMM and 
initiate the biosynthesis of the steroid hormones production (53, 54). The initial step in adrenal 
steroidogenesis is catalysed by cytochrome P450 side chain cleavage (P450SCC) also known 
as the cytochrome P450 11α-hydroxylase (CYP11A1), which converts cholesterol to 
pregnenolone (PREG) (7, 53, 54). PREG then serves as the precursor steroid metabolite to 
the three steroidogenic pathways, which will be discussed in Section 2.4. The conversion of 
cholesterol into PREG is also considered as the rate-limiting step of adrenal steroid 
metabolism and is highly dependent on the availability of free cholesterol (7, 18, 53, 54). 
Excess of free cholesterol will be esterified and stored in a lipid droplet by the enzyme, 
acyl-coenzyme A cholesterol acyltransferase (ACAT). If, however, the body requires a high 
amount of free cholesterol for adrenal steroid metabolism, HSL is activated and converts 
cholesterol esters in the lipid droplet to free cholesterol (53, 54, 60). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2
3  
3
Figure 8. Representation of the utilization of free cholesterol for adrenal steroid metabolism. LDL cholesterol esters 
bind to the LDL receptor, where they enter the cell via endocytosis. Free cholesterol is transported from the OMM 
to the IMM, via the protein, StAR. HDL cholesterol esters enter the cell via the SR-B1 receptor. Once in the cell, it 
can be stored as a lipid droplet, or it can be converted to free cholesterol by the enzyme, HSL. Only free cholesterol 
can enter the IMM. Free cholesterol can also be synthesized de novo from acetate in the ER and it can be stored 
as a lipid droplet by the enzyme, ACAT. Reproduced from (53). 
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2.4 Adrenal steroid metabolism  
In each zona of the adrenal cortex, there are two main types of enzymes that facilitate the 
biosynthesis of adrenal steroid hormones. These enzymes are known as cytochrome P450 
enzymes and hydroxysteroid dehydrogenases (53, 54, 61–63). A schematic representation of 
the steroid hormone biosynthesis in the adrenal cortex is shown in Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once cholesterol enters the IMM via the StAR protein, CYP11A1 converts cholesterol into 
PREG in three successive mono-oxygenase reaction; firstly, cholesterol is hydroxylated at 
C22, followed by a hydroxylation at C20 and finally, cleavage of the C20-22 bond by CYP11A1 
to produce the adrenal steroid precursor, PREG (53, 60). The conversion of cholesterol into 
PREG is classified as the rate-determining step of adrenal steroid metabolism as it regulates 
the rate at which the overall reactions in the adrenal cortex proceed (7, 54).  
Δ5 
Figure 9. Adrenal steroidogenesis pathway. All steroid hormones are derived from cholesterol by a network of 
enzyme-catalysed reactions. Reproduced and adapted from (54). 
Δ4 
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PREG travels from the mitochondria to the smooth ER, where the pathway by which PREG is 
metabolised is modulated by trophic (peptide) hormones (53). The release of the trophic 
hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH), play a significant 
role in androgen production. Furthermore, angiotensin II and potassium ions, control the 
biosynthesis of ALDO in the zona glomerulosa, whereas the adrenocorticotropic hormone 
(ACTH) regulates glucocorticoid biosynthesis (CORT and cortisol) in the zona fasciculata (53, 
60).  
The pathways by which PREG is converted to the respective adrenal steroid hormones in the 
different adrenal zone are the following: 
Zona reticularis  
In the zona reticularis of the adrenal cortex, PREG is converted to 17α– hydroxy-pregnenolone 
(17OH-PREG) by cytochrome P450 17α-hydroxylase (CYP17A1), which hydroxylates PREG 
at C17. 17OH-PREG is further metabolized by the 17,20 lyase activity of CYP17A1 to yield 
the adrenal androgen precursor, DHEA. 3β-hydroxysteroid dehydrogenase or 
3β-hydroxysteroid dehydrogenase Δ4,5-isomerase (3βHSD2) converts the Δ5 -steroid 
substrate, DHEA at C3, to the Δ4 -steroid product, A4 (7, 18, 53, 54). 
Zona glomerulosa 
In the zona glomerulosa 3βHSD2 converts PREG into progesterone (PROG) via an oxidation 
and isomerization reaction. Cytochrome P450 21-hydroxylase (CYP21A2) converts PROG 
into 11-deoxycorticosterone (DOC) via a hydroxylation reaction at C21. DOC moves back into 
the mitochondria where cytochrome P450 aldosterone synthase (CYP11B2) catalyses firstly 
the hydroxylation at C11 and the subsequent hydroxylation and oxidation reaction at C18 
resulting in the final conversion of DOC into ALDO (7, 18, 53, 54). 
Zona fasciculata 
The glucocorticoids are produced in the zona fasciculata from two different Δ4 -steroid 
substrates, PROG and 17α-hydroxy-progesterone (17OH-PROG). PREG and 17OH-PREG 
are converted by 3βHSD2 to PROG and 17OH-PROG. PROG is converted to DOC by 
CYP21A2 as previously mentioned, while 17OH-PROG is converted to 11-deoxycortisol by 
the same enzyme. PROG can also be converted to 17OH-PROG by CYP17A1. Both DOC 
and 11-deoxycortisol move to the mitochondria, where CYP11B1 catalyses the hydroxylation 
at C11 of both DOC and 11-deoxycortisol thus yielding CORT and cortisol, respectively (7, 18, 
53, 54). 
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2.5 The regulation of glucocorticoid biosynthesis via ACTH 
ACTH plays a significant role in the biosynthesis of glucocorticoids in the zona fasciculata of 
the adrenal glands. Stress, circadian factors, low glucose levels and inflammation are all 
examples of factors that can activate the trophic hormone (7, 54, 64). The mechanism of the 
ACTH-action is under the control of the hypothalamus, the anterior pituitary and the adrenal 
cortex, better known as the HPA-axis Figure 10 (7, 54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucocorticoid levels regulate the secretion of ACTH through a negative feedback system (7, 
18, 64). High glucocorticoid levels in plasma will inhibit the HPA-axis, whereas low 
glucocorticoid levels will activate the system (54). The activation of the HPA-axis, initiates the 
secretion of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) from the 
hypothalamus, which in turn stimulates the release of ACTH from the anterior pituitary gland 
(7, 54, 59).  
The release of ACTH affects the cells of the zona fasciculata in two ways: ACTH increases 
the permeability for certain ions to enter the membrane of the zona fasciculata and ACTH 
stimulates the production of cyclic adenosine monophosphate (cAMP) through the activation 
of adenylate cyclase. The production of cAMP results in the activation of a protein kinase A 
Figure 10. Schematic representation of the HPA-axis. Reproduced from (64). 
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signalling cascade which exerts both chronic and acute steroidogenic effects on the control of 
glucocorticoid production (7, 53, 60).  
The acute steroidogenic response occurs within minutes and is characterized by the activation 
of the HSL and the rate-limiting enzyme, CYP11A1. The esterase activity of HSL increases 
the supply of free cholesterol in the steroidogenic cell, while CYP11A1 utilizes the free 
cholesterol for glucocorticoid production (7, 18, 65). Evidence has further revealed that the 
chronic activation of the ACTH steroidogenic responses alter the cytochrome P450 enzymes 
expressed in the adrenal cortex at a mRNA level, resulting not only in an altered production of 
adrenal steroid hormone, but also an altered steroid flux in the adrenal gland (18, 54, 65). 
  
  
Perturbations of the HPA-axis, glucocorticoid receptor levels, or the expression and/ or activity 
of the enzymes involved in glucocorticoid production, can result in abnormal glucocorticoid 
levels, which can cause severe clinical conditions (54). In the case of “Grootlamsiekte” and 
the contraceptive action of the natural compounds of Salsola tuberculata in rats, inhibited the 
conversion of DOC and deoxycortisol to CORT and cortisol, respectively (7, 18, 27). In the 
next section, the importance of cytochrome P450 enzymes will be discussed.  
2.6 Cytochrome P450 enzymes 
The cytochrome P450-dependent enzymes involved in adrenal steroid metabolism belong to 
a large family of hemoproteins, which catalyse various hydroxylation reactions in both 
prokaryotic and eukaryotic organisms (7, 18, 54).  
The discovery of cytochrome P450 enzymes was first reported independently by Klingenberg 
and Garfinkel in 1958, who revealed an intense absorption at 450 nm when carbon monoxide 
(CO) was bubbled through a sodium dithionite reduced suspension of rat liver microsomes 
(66, 67). The unique spectral properties of cytochrome P450 enzymes were, however, 
identified by Omura and Sato (68) who concluded that the newly discovered heme pigment 
was a b-type cytochrome(s). Evidence obtained during their research showed a maximum 
absorbance at 450 nm when the heme pigment was in a reduced form and complexed with 
CO. Because the pigment absorbed maximally at 450 nm, the name cytochrome P450 was 
given to the new b-cytochromes. Omura and Sato further revealed that treating cytochrome 
P450 containing microsomes with detergent gave rise to an inactive solubilized form, known 
as cytochrome P420 (P420). The membrane bound cytochrome P450 enzyme could therefore 
be distinguished from its solubilized (and active) form, since the P420 enzyme absorbed 
maximally at 420 nm under the same conditions (68).  
Further investigations into the physiological function of cytochrome P450 enzymes revealed 
that the heme-pigment was the oxygen-activating component in various oxygenation 
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reactions. In 1964, Harding discovered cytochrome P450 enzymes in the mitochondria of the 
adrenal gland, where they served as the oxygen-activating component of the three 
mitochondrial cytochrome P450 enzymes systems, CYP11A1, CYP11B1 and CYP11B2 (69).  
2.6.1 Active site of cytochrome P450  
The distinct spectral and catalytic properties of all cytochrome P450 enzymes can be attributed 
to the unique conformation of the heme active site (Figure 11) (7, 18, 68). 
The active site of a cytochrome P450 enzyme is comprised of an oxidized iron (Fe3+) atom in 
the centre of a highly hydrophobic protoporphyrin IX ring (7, 18, 70, 71). The protoporphyrin IX 
ring structure is bound to the enzyme by hydrophobic forces and coulombic attractions, while 
the iron is bound to the protoporhyrin IX ring by four coordinate ion-covalent bonds (7, 18). 
The iron atom, however, can still bind two ligands, one in the fifth and the other in the sixth 
axial position. The sixth axial position is co-ordinated to the iron by an easily exchangeable 
ligand, such as water, and under reduced conditions, CO can occupy the sixth position. The 
fifth axial position, however, is different from other cytochrome enzymes, as the polypeptide 
chain of the enzyme contains a conserved cysteine residue in which the sulphur is a thiolate 
anion forming a cysteinyl ligation to the heme iron (7, 18, 70, 71). 
 
 
 
 
 
 
 
 
 
 
The oxidation state of the heme iron and the thiolate axial ligand directly influences the unique 
spectral properties of P450-dependent enzymes. Iron exists in two oxidation states, namely, 
the ferrous iron (FeII) and the ferric iron (FeIII). In a substrate -free environment, the ferric iron 
Figure 11. Schematic representation of the active site of cytochrome P450 dependent enzymes. The 5 th axial 
position is co-ordinated to the iron by the thiol anion of a cysteine residue, whereas the 6th axial position is 
co-ordinated with a water molecule. Redrawn from (7). 
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has five valence electrons in the 3d orbital, whereas the ferrous iron has six (Figure 12) (7, 
18, 72).  
 
 
 
 
 
The occupancy of valence electrons in the 3d orbital is influenced by the binding of a substrate 
or inhibitor to the iron. The spin state of iron is therefore influenced directly by the behaviour 
of the valence electrons in the 3d-orbital. When iron is bound to a substrate, the spatial 
arrangement of the 3d orbitals attains different levels of energy in relation to the substrate. 
This is known as field splitting energy (Δ). Once a substrate binds to iron, the orbitals are split 
(by the field splitting’s energy) into two groups, two higher lying and three lower lying orbitals 
(Figure 13) (7, 18, 72).  
 
When the (Δ) is relatively small in comparison to the energy required for the electrons to pair 
(spin-pairing of electrons (P)), less energy is required for the five electrons of FeIII and the six 
electrons of FeII to fill each orbital first before pairing. The iron will therefore be in a high-spin 
state with maximally unpaired electrons. The high-spin state FeIII iron has five unpaired 
electrons, whereas FeII iron has four unpaired electrons (Figure 14) (7, 18, 72).  
Figure 13. Energy levels of the valence electrons in the 3d orbital influence by the field splitting energy (Δ). Image 
redrawn from (7). 
Figure 12. Distribution of electrons in the 3d orbital of the ferric- (FeIII) and ferrous (FeII) iron, respectively. Image 
redrawn from  (7). 
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Alternatively, when (Δ > P), the valence electrons will occupy all the lower energy orbitals first, 
before moving to a higher orbital, giving rise to a low spin state iron with minimum unpaired 
electrons. The low-spin state FeIII iron has one unpaired electron, whereas FeII has no 
unpaired electrons (Figure 15) (7, 18, 72).  
 
 
 
 
 
 
 
The valence electrons in the 3d orbital also influence the position of the heme-iron in the cavity 
of the protoporhyrin IX ring. The space of the protoporphyrin IX ring cavity is in a fairly rigid 
hexa-coordinated octahedral shape, with a diameter of 2.02 Å. As the valence electrons of the 
low-spin state iron do not occupy the higher lying orbitals, the low-spin form of the iron is more 
compact than the high-spin form, with a diameter of 1.91 Å. The space in the protoporhyrin IX 
ring is large enough to accommodate the low-spin state iron. Conversely, the high-spin state 
iron, which has a diameter of 2.6 Å cannot fit into the space of the protoporhyrin IX ring cavity. 
The substrate causes the displacement of the high-state iron out of the plane of the 
protoporphyrin IX ring cavity and changes the hexa-coordinated octahedral shape of the active 
site to a penta-coordinated square-pyramidal shape. The low-spin state iron is 0.3 Å out of the 
 
Figure 15. Distribution of valence electrons in the 3d orbital in FeIII and FeII when the field splitting energy (Δ) is 
larger than the spin-pairing energy (P). Image represents the low-spin state of the iron. Redrawn from (7). 
 
Figure 14. Distribution of valence electrons in the 3d orbital in FeIII and FeII when the field splitting energy (Δ) is 
smaller than the spin-pairing energy (P). Image represents the high-spin state of the iron. Redrawn from (7). 
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plane of the protoporphyrin ring cavity, whereas the high-spin state iron is approximately 0.7 
Å out of the plane (Figure 16) (7, 18, 72) . 
 
 
 
 
 
 
 
 
The spin state of iron is, therefore, influenced by two factors, namely: the oxidation state of 
the iron, and the specific substrate in the active site. The low- and high-spin state iron is 
characterised with specific spectral properties. Therefore, changes brought about by a specific 
substrate or inhibitor can be determined spectrophotometrically. The unique properties of 
P450-dependent enzymes give rise to difference spectra, which can be used to determine the 
spin state of the iron and the mechanism of action of these enzymes (7, 18, 72). The bio-assay 
used to determine the influence of Salsola tuberculata and CpDA on the terminal reaction of 
the glucocorticoid biosynthesis pathway, were based on these unique spectral properties of 
CYP11B1. Details of these assays will be described in Section 2.6.4. 
2.6.2 Catalytic cycle of cytochrome P450 enzymes 
Cytochrome P450 enzymes serve as the biocatalyst in mono-oxygenase reactions by 
incorporating a single oxygen atom into a non-polar substrate (RH), while reducing the second 
oxygen atom into water (7, 71, 73). Due to the unique structure of the hemo-protein (oxygen 
activation site), P450-dependent enzymes are the only heme-containing enzymes that can 
catalyse these mono-oxygenase reactions (7, 18, 73). The general redox reaction, catalysed 
by cytochrome P450 mono-oxygenases, is summarised in the following equation: 
RH + O2 + NADPH + H+ → ROH + H2O + NADP+ 
For the hydroxylation reaction to occur in adrenal steroid metabolism, the P450-dependent 
enzyme requires a source of electrons and an electron transport system. As mentioned in 
section 2.4, P450-dependent enzymes are found both in the ER and mitochondria of the 
adrenal cortex and can therefore be classified as microsomal or mitochondrial cytochrome 
P450 enzymes (53). Microsomal cytochrome P450 enzymes are expressed in the brain, lungs, 
Low-spin state iron High-spin state iron 
Figure 16. Representation of the position of the iron in low- and high-spin state.  Upon substrate binding, the iron 
moves out of the plane of the protoporphyrin IX ring cavity. Redrawn from (7). 
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liver and adrenals, whereas mitochondrial cytochrome P450 enzymes are found in the liver, 
kidney and adrenal (7, 70). 
Not only are the microsomal and mitochondrial cytochrome P450 enzymes substrate specific, 
but they also require a different mechanism of electron transport to support the cytochrome 
P450 catalysed reactions (7, 18, 53). However, for the purpose of this study only the electron 
transport system of the adrenal mitochondrial cytochrome P450 enzymes (CYP11A1, 
CYP11B1 and CYP11B2) will be discussed. 
The mitochondrial cytochrome P450 enzymes utilize the reducing equivalents of NADPH via 
an electron transport chain which is embedded in the IMM (7, 18, 74). The mitochondrial 
electron transport chain is comprised of ADXR, ADX and the specific mitochondrial 
cytochrome P450 enzyme (75). ADXR is a NADPH-specific flavin adenine dinucleotide (FAD) 
containing flavoprotein, whereas ADX is a non-heme iron-sulphur protein (76). The 
flavoprotein contains one mole of FAD per mole of protein and has a molecular weight of 
approximately 52 000 Da (76, 77). During the hydroxylation cycle, the flavoprotein is capable 
of accepting a maximum of two electrons from NADPH, while the resulting NADP+ remains 
bound to the reduced flavoprotein. The reaction complex is represented as follows: 
 
The non-heme protein contains two iron atoms and two moles sulphur per mole protein, and 
has an approximate molecular weight of 12 000 Da (7, 18, 78). Together, ADXR and ADX 
form a biomolecular complex and function as a short electron transport chain.  
Upon substrate binding (Figure 17), two electrons are transferred from NADPH to the flavin 
protein in two separate cycles. The reduced ADXR transfers the electrons to the oxidised ADX 
(76, 78). The reduction of the iron-sulfur centre weakens the interaction between the 
biomolecular complex, thus promoting the dissociation of the reduced mobile shuttle. The 
reduced ADX re-associates with the substrate bound enzyme (CYP11A1, CYP11B1 or 
CYP11B2) and donates a single electron for the catalytic reaction. In the second phase of 
electron transfer, an electron from NADP+ is transferred to ADXR. The dissociation and 
association of ADX with the flavoprotein and cytochrome P450 enzyme respectively allows for 
the second cycle of electron transfer (7, 18, 76, 78). 
  
NADP+         ADXR (FADH2) 
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The mitochondrial electron transport system is also capable of reducing other mitochondrial 
proteins, such as cytochrome c (7, 79). Cytochrome c is a heme-containing protein with a 
molecular weight of 12 000 Da (79, 80). As cytochrome c and the mitochondrial electron 
transport system are located on opposite sides of the IMM, there is no physiological relevance 
in the reduction of this heme-containing enzyme (7, 79, 80). Cytochrome c can therefore be 
used as a mechanistic probe to determine the manner in which the adrenal mitochondrial 
hydroxylation system is influenced by CpDA, the cytochrome P450 inhibitor used in this study 
(80). If no inhibitory effect is observed in the reduction of cytochrome c, one would conclude 
that CpDA affects only the spin state of the purified CYP11B1 and not the mitochondrial 
electron transport chain. In Chapter 4, studies that explored the influence of CpDA, and the 
R- and S-enantiomer of CpDA on the mitochondrial electron transport chain by using 
cytochrome c as an electron acceptor are described. 
2.6.3 The mechanism of P450-dependent hydroxylation reactions 
The proposed representation for the mechanism of action of the catalytic cycle of 
P450-dependent enzymes, is shown in Figure 18.  
 
 
 
Figure 17. Schematic representation of the adrenal steroidogenic short electron transport system in the 
mitochondria. (E) represents the mitochondrial enzyme, CYP11B1. (S) denotes the natural substrate, DOC. ADXR 
is the NADPH-specific FAD containing flavoprotein, whereas ADX is the non-heme protein. Adapted from (7). 
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The first step in the catalytic cycle entails the binding of a hydrophobic substrate, (RH), to the 
oxidised form of the cytochrome P450 enzyme Figure 18 (1). This initiates the transfer of a 
single electron from NADPH via the short electron transport system to the enzyme-substrate 
complex, which leads to the reduction of the ferric iron (low-spin state) to the ferrous (high-
spin state) iron Figure 18 (2). At this point (Figure 18 (3)), a single oxygen molecule binds to 
the reduced enzyme-substrate complex, forming a superoxide complex with the ferrous iron 
(Fe2+ - O2), which slowly converts to a more stable ferric enzyme-substrate complex 
(Fe3+ - O2-). The second electron from NADP+ is required at this point to balance the 
stoichiometry of this redox equation, by converting the Fe3+ - O2- - complex to produce the rate-
limiting complex, Fe3+ - O22- (Figure 18 (4)).  
The oxygen at this stage will react with two protons from the surrounding environment, causing 
the oxygen-oxygen bond to break. The one oxygen atom is released as water (Figure 18 (5)), 
and the other oxygen atom (“activated oxygen”) is inserted into a carbon-hydrogen bond of 
the substrate, yielding a hydroxylated product (ROH) (Figure 18 (6)). The completion of the 
catalytic cycle, entails the dissociation of the hydroxylated product and the regeneration of the 
cytochrome P450 dependent enzyme (Figure 18) (7) (7, 18, 71). 
  
Figure 18. The catalytic cycle of P450-dependent hydroxylation reactions. The iron atom is a representation of 
the enzyme, whilst the RH (red block) and ROH (blue block) represent the substrate and the product, respectively. 
Modified image from (71). 
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2.6.4 Spectral properties of cytochrome P450 enzymes 
In general, the heme-containing proteins, with the exception of cytochrome P450 enzymes, 
show substantial consistencies in their absorbance spectra (7, 18). The “usual” heme-
containing proteins can be divided into two main groups, namely: the hemo-proteins 
(cytochromes) that function as electron carriers during processes such as oxidative reactions; 
and the heme-containing proteins (haemoglobin and peroxidase) that function as oxygen 
carriers and oxidizing agents, respectively. The oxidized form of the first group will exhibit a 
ferric low-spin type absorbance spectrum when oxidized and a ferrous low-spin type when it 
is reduced. Alternatively, the oxygen carriers and oxidizing hemo-proteins elicit a ferric high-
spin and ferrous high-spin type spectrum when they are in their oxidized and reduced forms, 
respectively (7, 18, 70). 
In contrast, the cytochrome P450 enzymes possess unique spectral properties which can be 
summarized as follows (7, 18, 70): 
 As mentioned in Section 2.6, cytochrome P450 enzymes exhibit a maximum peak at 
450 nm after the reduction with dithionite and treatment with CO, whereas a maximum 
peak at 420 nm is observed in the “usual” hemo-proteins. 
 Unlike other hemo-proteins, which only exhibit spin state change upon cyanide, azide 
and fluoride binding, various substrates such as drugs, toxins and steroids, can induce 
spin state changes in cytochrome P450 enzymes. 
 Variations in pH and ionic strength can also cause changes in the spin state of 
cytochrome P450 enzymes. 
 Both the ferric high-spin and low-spin forms of the cytochrome P450 enzymes are 
converted to a ferrous high-spin form, upon reduction with dithionite or NADPH. 
 The binding of ethyl isocyanide to the reduced form of cytochrome P450 enzyme will 
change the peak at 450 nm into two peaks, with an absorbance at 430 nm and 453 
nm, respectively. 
The unique spectral characteristics of cytochrome P450 enzymes suggest that the 
environment surrounding the active site is highly dynamic and therefore allows for spin state 
changes to occur upon substrate binding. The spectral changes can be attributed to the 
interaction of the prosthetic group with specific amino acids (histidine, methionine and 
cysteine) of the apoprotein in the dynamic hydrophobic environment of the active site. The 
thiolate anion, provided by a cysteine residue is responsible for the unique spectral 
characteristics of cytochrome P450 enzymes (70). 
Difference spectroscopy is used to investigate the unique spectral characteristics of 
P450-dependent enzymes. There are two main types of difference spectra employed to study 
Stellenbosch University  https://scholar.sun.ac.za
 
 
26 
 
cytochrome P450 enzymes – the cytochrome P450 activity assay, also known as the CO-
induced difference spectra, and the substrate-induced difference spectra. 
2.6.4.1 Cytochrome P450 activity assay - CO-induced difference spectra 
A CO-induced difference spectrum of adrenocortical mitochondria provides information on the 
concentration and activity of the cytochrome P450 enzymes (68, 70). The concentration of 
cytochrome P450 is determined by bubbling CO through the adrenocortical mitochondria 
preparation, prior to the reduction by either sodium dithionite or NADH (70). When the enzyme 
is active, a peak with a maximum at 450 nm is observed, with a deep trough at 405 nm and a 
shallow trough at approximately 480-520 nm (Figure 19). Alternatively, when the cytochrome 
P450 enzyme is converted to its inactive form, a peak with a maximum peak at 420 nm will be 
observed.  
 
 
 
 
 
 
 
 
 
 
2.6.4.2 Substrate-induced difference spectra 
The spectral properties of cytochrome P450 enzymes can provide valuable information about 
the mechanism of action of a particular test compound (7, 15, 18, 70). The unique spectral 
properties of CYP11B1 facilitated the development of two spectral assays, which served as a 
reliable, sensitive and rapid approach to screen for biological activity for the active compounds 
in Salsola tuberculata (7, 15).  
Figure 19. CO-induced dithionite reduced difference spectrum of mitochondrial cytochrome P450 from ovine 
adrenal. Maximum peak at 450 nm denotes an active cytochrome P450 enzyme (red), whereas a maximum peak 
at 420 nm represents the inactive form (blue), known as cytochrome P420. Redrawn from experimental work. 
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The first two assays were based on the spectral properties of CYP11B1 and are denoted as 
Spectral Assay A (DOC-induced difference spectrum) and Spectral Assay B (Inhibitor-induced 
difference spectrum). These bio-assays were based on the ability of a test compound to bind 
to the active site of CYP11B1 and induce a difference spectrum. In order to induce a difference 
spectrum, active cytochrome P450 enzyme is required (maximum peak at 450 nm). If, 
however, the enzyme is in its inactive form (maximum absorbance at 420 nm), no substrate-
induced difference spectrum will be observed. The type of substrate-induced difference 
spectrum is therefore dependent on the structure of substrate used, the source of cytochrome 
P450 and the spin state of the enzyme (7, 17, 18, 27, 70). The characteristic absorbance 
maximum, minimum and change in spin state of a substrate-induced difference spectrum are 
summarized in Table 1.  
Table 1. Characteristics of the substrate- and inhibitor-induced difference spectrum of cytochrome P450 enzymes. 
Redrawn from (7). 
 
2.6.4.2.1 Spectral assay A: DOC-induced difference spectrum 
Spectral assay A is used to determine the effect of an inhibitor on the binding of a substrate 
(DOC) to CYP11B1. When a substrate such as DOC binds to CYP11B1 it forms an 
enzyme-substrate complex, and changes the ferric iron (low spin state) to a ferrous iron (high 
spin state). It is important to note that the intensity of the substrate-induced difference 
spectrum is directly proportional to the concentration of substrate. The high spin state of the 
iron will elicit a Type I spectrum, which is characterized by an absorbance maximum at 
385-390 nm and an absorbance minimum at 420 nm (Figure 20) (7, 17, 18).  
An inhibitor will decrease the amplitude at the absorbance maxima value and increase the 
amplitude at the absorbance minima value (17).  
2.6.4.2.2 Spectral assay B: Inhibitor-induced difference spectrum 
In general, a natural substrate will bind to its cytochrome P450 enzyme and elicit a Type I 
spectrum. However, some compounds such as inhibitors, can also elicit a difference spectrum 
in P450. The inhibitor binds to the enzyme and forms an enzyme-inhibitor complex, which 
 Maximum absorbance Minimum absorbance Spin state change 
 Type I 385-390 nm 420 nm Low to high 
 Type II 430 nm 390 nm High to low 
Type II 
(Modified) 
409-445 nm 365-410 nm High to low 
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stabilizes the low-spin state of the iron and induces a typical Type II difference spectrum. The 
Type II difference spectrum is characterized by an absorbance maximum and minimum of 430 
nm and 390 nm, respectively (Figure 21) (7, 17, 18).  
Investigations into the biological properties of the active compounds from Salsola tuberculata 
and CpDA revealed that both test compounds inhibit the DOC-induced difference spectrum 
and also induced a Type II difference spectrum, meaning that it stabilized the low-spin state 
of the enzyme (27, 28). The spectral properties of these assays was used to investigate and 
compare the effect of CpDA and the R- and S-enantiomers on both spin states of CYP11B1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Representation of Spectral Assay A. CpDA inhibits the binding of DOC to CYP11B1.  
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Although difference spectroscopy serves as a reliable and rapid technique to investigate the 
substrate and inhibitor interaction with CYP11B1, there are a number of restrictions and 
precautions to be considered before recording and interpreting spectra (7, 17, 70). These 
restrictions and precautions are summarized as follows: 
a. Only optically matched cuvettes can be used during the recording of a difference 
spectrum. Any discrepancy in the cuvettes could result in an inaccurate recording of 
the baseline, therefore affecting the recording of the difference spectrum itself. 
b. As the recording of the difference spectra is influenced by pH, ionic strength, 
detergents, the volume and concentration of the solvent added should be considered. 
The enzyme may be influenced by the organic solvent should the substrate or 
compound not be soluble in an aqueous solution. In addition, the contents in the 
sample and reference cuvettes should always be equal before baseline recording. 
After baseline recording, substrate should be added to the sample cuvette and an 
equal volume of organic solvent should be added to the reference cuvette. The 
intensity of the substrate-induced difference spectrum may also be affected by the 
volume of solvent. Therefore, a small volume of the solvent and substrate should be 
added to minimize interference. 
Figure 21. Representation of Spectral Assay B. CpDA induced a Type II-induced difference spectrum with an 
absorbance maximum at 430 nm and absorbance minimum at 412 nm.   
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c. In a partially pure mitochondrial preparation, contaminating proteins such as 
cytochrome c oxidase, haemoglobin, and P420, may interact with the added substrate 
and interfere with the difference spectra recorded. 
d. As the mitochondrial cytochrome P450 enzymes are membrane bound and in 
suspension, sedimentation of protein may occur during recording. Sedimentation of 
the mitochondrial preparation may be prevented by sonicating the preparation or 
decreasing the mitochondrial cytochrome P450 concentration prior to recording 
difference spectra. 
e. Only specialized instruments can be used to record the difference spectra of turbid 
samples. The instrument should ensure maximum sensitivity throughout the 
absorbance and wavelength ranges for each preparation. 
 
The unique spectral properties of CYP11B1 served as the basis of bio-assays 
used in this study. In Chapter 3, experiments are described that utilised a partially purified 
mixture of CYP11B1 from ovine adrenals to screen for biological activities of CYP11B1 
inhibitors (CpDA and the enantiomers of CpDA). Chapter 4 describes experiments used to 
distinguish between the biological activities of the R- and S-enantiomers of CpDA using a 
highly purified substrate-free CYP11B1 preparation. 
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CHAPTER 3 
Synthesis of a racemic mixture of CpDA and the chiral 
resolution of the R- and S-enantiomers of CpDA  
 
3.1 Introduction 
CpDA (2-(4-acetoxyphenyl)-2-chloro-N-methyl-etylammonium chloride) is a synthetic 
analogue of the highly unstable and reactive aziridine precursor found in the African shrub, 
Salsola tuberculata (4, 26, 27). Like its natural counterpart, CpDA interferes with the binding 
of the substrates, DOC and/or deoxycortisol, to CYP11B1, the terminal cytochrome P450 
enzyme in the glucocorticoid biosynthesis pathway. By using the spectral properties of 
CYP11B1, studies have shown that CpDA inhibits the DOC-induced difference spectra and 
induces a Type II difference spectrum on its own (27). Initial chemical investigations indicated 
that the activity of the synthetic compound could be attributed to the formation of an aziridine 
when the nitrogen of the ethylammonium moiety carries out a nucleophilic attack on C2 to 
yield the 2-(4-acetoxyphenyl)-1-methylaziridine, as shown in Figure 22. It was, however, later 
established that the cyclisation of the aziridine precursor of 2-(4-acetoxyphenyl)-1-
methylaziridine resulted in the inactivation of CpDA (Figure 22) (21, 24). As aziridines are 
reactive and chemically unstable compounds (24, 25), pH, light and oxygen influence the 
cyclization of CpDA.  
The biologically active and inactive forms of CpDA can be distinguished from one another by 
electrospray mass spectrometry (ES-MS), as the open-ring structure has a molecular ion at 
228/230, whereas CpDA in which the aziridine ring structure is intact has a molecular ion at 
192. Biological studies have, however, revealed that the steroid-binding globulins in plasma 
can stabilize the ring-opened form of CpDA (M+H]+ = 228), thereby enhancing its biological 
activity in vivo (4, 24, 28, 81).  
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At present, CpDA has been identified as a selective glucocorticoid receptor modulator with 
both anti-inflammatory and anti-cancer properties in numerous in vitro and in vivo studies. 
Nonetheless, the racemic mixture of CpDA has a restricted therapeutic range of ±1-15 mg/mL 
(30). Therefore, in an attempt to possibly enhance its therapeutic range, the R- and S-
enantiomers of CpDA were separated.  
Chirality or chiral originates from the Greek word cheir, which translates to “handedness” and 
is used to describe the non-superimposability of an object with its mirror image (49, 82, 83). 
In chemistry, chirality is used to describe two structurally, physically and chemically identical 
molecules and/or compounds that cannot be super-imposed on one another (48, 49, 84). The 
two identical molecules/compounds are referred to as stereoisomers and more specifically 
enantiomers (48, 49, 82). Enantiomers are formed when the chiral centre (asymmetric centre) 
is attached to four different substituents and for a molecule/compound to be chiral, it should 
have at least one chiral centre (49, 83, 84).  In most instances the different substituents will 
be attached to a carbon atom, while in some cases nitrogen, phosphorus and sulphur can also 
act as the asymmetric centre (49). Another important feature of enantiomers is that they exhibit 
optical activity, meaning that each enantiomer of a chiral compound can rotate polarized light 
by the same magnitude, but in an opposite direction (48, 49). Alternatively, an equal mixture 
(also known as racemic mixture or racemate) of both enantiomers of a specific chiral 
compound will be optically inactive (49, 82). The direction in which the enantiomers can 
polarise light can either be classified as dextrorotary (d or +) or levorotary (l or -), which is 
classified as rotating polarized light towards the right (clockwise) or left (anti-clockwise), 
respectively (49, 82). There are two ways by which the optical activity of an enantiomer can 
be determined, namely, through the use of a polarimeter or by circular dichroism. However, 
for both approaches a highly purified enantiomeric sample is required (49). 
Figure 22. Biologically active CpDA (2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride) in which 
the ring-opened aziridine precursor cyclises into biological inactive form of CpDA (2-(4-acetoxyphenyl)-1-
methylaziridine), with a ring closed structure. Redrawn from (28). 
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Enantiomers can further be distinguished from one another by their 3-D configurations in 
space (48, 82, 84). An important nomenclature system, known as the R/S-configuration 
system, has been employed to distinguish between the absolute 3-D configurations of the 
enantiomers by assigning the letter R or S to the chiral centres (48, 49, 83). The letters R and 
S originate from the Latin words rectus, meaning ‘right’ or ‘clockwise,’ and sinister, meaning 
‘left’ or ‘anti-clockwise’. The Cahn-Ingold-Prelog (CIP) sequence rules are used to determine 
whether the chiral centre is in an R or S configuration (49, 52, 83). These rules are based on 
re-orientating the four different substituents attached to the chiral centre in order of priority i.e. 
from highest to lowest molecular weight (highest = 1 to lowest = 4)  (48, 49, 82). If the priority 
of the substituents attached to the chiral centre ascend in a clockwise direction, the chiral 
centre is in the R configuration; alternatively, if the priority of the substituents ascends in a 
counter-clockwise direction, the configuration is designated as S (52, 83).  
In an achiral environment (non-living system), enantiomers have identical physical, chemical 
and biological properties (83, 85). However, as chirality is found in the most fundamental 
building blocks of life, such as amino acids, lipids, carbohydrates, as well as enzymes and 
receptors, the individual enantiomers of a chiral compound can behave differently in a living 
system (48, 83). Therefore, the R- and S-enantiomers of a chiral drug should be classified as 
two distinct compounds with different biological characteristics, unless proven otherwise (83). 
Figure 23 illustrates a theoretical interaction between the R- and S-enantiomers of a chiral 
drug and the binding site of a chiral enzyme. In this scenario, the R-enantiomer is biologically 
more active than the S-enantiomer, as the substituents of the R-enantiomer (A, B and C) 
directly interact with the binding sites of the chiral enzyme labelled a, b and c, respectively. 
However, as the S-enantiomer is in the “wrong” 3-D configuration, the C and A substituents 
do not interact with the a and c binding site of the enzyme. Therefore, in a racemic mixture, 
the S-enantiomer will be inactive, or in some cases cause severe side-effects. It was therefore 
deemed important and interesting to separate the R- and S-enantiomers of CpDA, as the 
single enantiomeric form could lead to a simpler and improved pharmacological profile (48, 
83). 
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Various techniques exist which can aid in the separation of the R- and S-enantiomers of a 
chiral compound. These techniques include, diastereomeric salt crystallization, bio-resolution, 
enzymatic kinetic-resolution, capillary electrophoresis, supercritical fluid extraction and 
chromatography. The separation of any given two enantiomers is not a simple task, as each 
chiral compound is different. Therefore, choosing a specific technique is dependent of the 
nature of the compound, the availability of resources and the time and cost of production (48, 
49). Due to the limited resources and the cost of production, diastereomeric salt crystallization 
was chosen to separate the R- and S-enantiomers of CpDA, as this technique is more time 
efficient and cost effective, when compared to other methods of chiral separation.  
In 1965, Ault used diastereomeric salt crystallization to separate the R- and S-enantiomers of 
racemic mixture of 1-phenylethylamine (Figure 24) (86). This separation was achieved by 
reacting 1-phenylethylamine with an optically pure form of L-(+)-tartaric acid, which produced 
two diastereomeric salt complexes i.e. (R)-amine, (R, R)-tartaric acid and (S)-amine, 
(R, R)-tartaric acid. In contrast to enantiomers, diastereoisomers have different 
physiochemical properties, and as such, the two salt complexes have different solubility in 
methanol. Figure 24 illustrates this conversion, whereby the (R)-amine, (R, R)-tartaric acid 
was more soluble in methanol and therefore stayed in solution, and the (S)-amine, (R, R)-
tartaric acid was less soluble and precipitated as crystals. Once the diastereomeric complexes 
were isolated from one another, the individual complexes were treated with an excess of 
sodium hydroxide (NaOH), which freed the individual amine salts from tartaric acid (86). As 
Figure 23. Theoretical interaction of the R- and S-enantiomers of a chiral drug on the drug binding sites of a chiral 
enzyme. The R-enantiomer aligns directly to the binding sites of the enzyme, whereas the C and A substitutes of 
the S-enantiomer do not. In this theoretical scenario, the R-enantiomer will be biologically active, whereas the 
S-enantiomer will be inactive. Adapted from (83). 
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1-phenylethylamine is structurally similar to CpDA, a modified approach was employed to 
separate the R- and S-enantiomers of CpDA.  
 
Due to the amount of CpDA required to separate the enantiomers and the cost involved in 
buying commercially available CpDA, it was financially more viable to synthesise a racemic 
mixture of CpDA. It must, however, be emphasized that CpDA readily cyclises into its inactive 
form under standard laboratory conditions (28). Therefore, to preserve the biological activity 
of CpDA precautionary steps were employed, which involved working in a dark and inert 
environment. The purity of CpDA was tested by using Q-ToF/ESI-MS and NMR spectroscopy. 
In addition, the spectral properties of CYP11B1 were used to screen for biological activity of 
CpDA.  
In this study CpDA was therefore synthesized after which the racemic mixture of CpDA was 
reacted with optically pure L-(+)-tartaric acid to produce diastereomeric salts, dissolved in 
methanol and separated by selective crystallization. The salts were converted to the 
respective enantiomers by treatment with hydrochloric acid (HCl) and the structures validated 
using Q-ToF/ESI-MS and 1H-NMR spectroscopy. Their respective biological activities were 
determined using the spectral properties of CYP11B1. 
Figure 24. Chiral separation of 1-phenylethylamine.  
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3.2  Experimental 
3.2.1 Materials and reagents 
All solvents used (unless otherwise specified) were of laboratory grade (>95% pure) and 
purchased from trustworthy scientific companies. Acetone and ethanol absolute (analytic 
grade) were purchased from Merck Millipore (South Africa). Acetyl chloride, diethyl ether 
(analytic grade), hydrogen chloride, methanol (analytic grade) and glacial acetic acid (analytic 
grade) were obtained from Sigma- Aldrich Chemical Co. (St. Louis, MO, USA). Anti-bumping 
granules were purchased from BDH Chemicals Ltd Poole (England). Deionised water (dH2O) 
was obtained from an in-house Milli-QTM water purification system. Wilmad® NMR tubes (5 
mm diameter) and deuterium oxide (99.9 atom %D), (±)-synephrine (≥ 98%), L-(+)-tartaric acid 
(≥99.5%) and DOC (≥ 97%, HPLC) were purchased from Sigma – Aldrich (St. Louis, MO, 
USA).  
Fresh ovine adrenals were collected from Tomis Abattoir & Fresh Meats Wholesalers 
(Hermon, South Africa). A Beckman Coulter Avanti® J-E centrifuge was used for all 
centrifugation procedures. The mitochondrial cell membranes were disrupted by sonicating 
with a Branson B12 sonifier. Spectral assays were recorded on a Cary 100 UV-visible dual 
beam spectrophotometer from Agilent Technology (South Africa). Samples were concentrated 
on a Techne sample concentrator DB-3 or CentriVap benchtop vacuum concentrator from 
Labconco. The protein concentration of mitochondrial preparations was determined by using 
the Pierce bicinchoninic acid (BSA) protein quantification kit from Thermo Fisher Scientific 
(Rockford Ill, USA). Q-ToF/ESI-MS and NMR analyses were all performed at the Central 
Analytic Facility (CAF) at Stellenbosch University. The facility provided all materials and 
reagents needed for the analyses. 
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3.2.2 Methods 
3.2.2.1 Synthesis of CpDA 
CpDA was synthesized by a method previously published (24, 28). The schematic 
representation of the synthesis of CpDA is shown in Figure 25. 
 
(±)-Synephrine (10 g; 59.81 mmol) was dissolved in glacial acetic acid (27 mL, 28.35 g, 
0.472 mol), whilst cooling down the entire mixture to 10ºC on a water bath. Acetyl chloride 
(27 mL, 29.7 g, 0.378 mol) was slowly added to the mixture in a dropwise manner, while stirring 
continuously under an inert atmosphere. The temperature was kept below 30ºC. A clear 
solution was formed within the first hour of this reaction and within 12 hours a white precipitate 
was produced. The precipitate was collected by filtration under nitrogen and washed three 
times with anhydrous cold ether (20 mL), followed by three consecutive washes with 
anhydrous cold acetone (20 mL). The white powder was kept in a vacuum desiccator (over 
silica gel) for 12 hours before storage at -80ºC.The powder was highly hygroscopic and readily 
decomposed following the absorption of moisture or when it was left at room temperature. The 
structure and purity of CpDA were verified by 1H-NMR,13C-NMR and Q-ToF/ ESI-MS. 
 Product: White powder; Yield: 13.229g, 57.76 mmol, 83.72%. 
 ESI-MS: (m/z) [M+H]+ calculated for C11H15ClNO2 (CpDA, open-ring structure of 
aziridine): 228.0791 g/mol, found 228.0764 g/mol.  
 1H-NMR (600 MHz, D2O) δ 2.38 (s, 3H), 2.84 (s, 3H), 3.65 (dd, J = 13.5, 9.9 Hz, 1H), 
3.77 (dd, J = 13.5, 9.9 Hz, 1H), 5.45 (dd, J = 9.9, 4.4 Hz, 1H), 7.26 (d, J = 4.8 Hz, 2H), 
7.63 (d, J = 4.8 Hz, 2H), 
 13C-NMR (600 MHz, D2O) δ=21.07, 33.80, 49.66, 53.22, 55.14, 57.30, 72.15, 123.41, 
128.36, 129.59, 134.17, 135.40,151.48, 173.92. 
  
Figure 25. Schematic representation of the synthesis of CpDA. 
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3.2.2.2 Separation of the R- and S-enantiomers of CpDA  
The R- and S-enantiomers of CpDA were separated by modifying the previously published 
diastereomeric salt crystallization method as applied to 1-phenylethylamine (86). The 
schematic representation of the chiral resolution of the R- and S-enantiomers are depicted in 
Figure 26. 
 
Methanol (9.88 mL) was added to 0.691 g L-(+)-tartaric acid in a 50 mL round bottom flask. 
The mixture was heated to ±40°C (below boiling point) in a water bath and stirred with a 
magnetic stirrer for 10 minutes or until a homogenous solution was obtained. A racemic 
mixture of CpDA (1 g) was cautiously added to the hot methanol solution. The flask was 
stoppered and the reaction mixture stirred for approximately 60 minutes until the reaction 
mixture was clear. The homogenous reaction mixture was allowed to cool to room 
temperature. The (-)-amine-(+)-hydrogen tartrate is less soluble in methanol and thus 
crystalized out, whilst the (+)-amine-(+)-hydrogen tartrate remained in solution. Following, 
Figure 26. Schematic representation of the chiral resolution of the R- and S-enantiomers of CpDA. 
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centrifugation at 5000 x g for 10 minutes, the precipitate (crystals) were collected by vacuum 
filtration using a small Buchner funnel. The crystals were subsequently mixed with a 6 M 
aqueous hydrogen chloride (HCl) solution (10 mL). The pH change protonated the tartaric 
acid, making it less soluble in water. The tartaric acid was extracted with three 20 mL portions 
of ether. Any remaining ether was removed, by passing nitrogen over the surface of (-)-amine 
solution. The (-)-amine solution was further concentrated using a speed vac concentrator. The 
total yield of the (-)-amine was 41.5 mg (4.15%). The (+)-amine-(+)-hydrogen tartrate in 
solution was treated in the same way to remove the tartaric acid. The final yield of the (+)-
amine product was 480 mg (48%). 
 R-enantiomer – clear gel-like compound, highly hygroscopic; Yield 480 mg, 48%.  
 S-enantiomer – clear gel-like compound; highly hygroscopic; Yield 41.5 mg, 4.15% 
 ESI-MS of the R- and S-enantiomers: (m/z) [M+H]+ calculated for C11H15ClNO2 
(CpDA, open-ring structure of aziridine): 228.0791 g/mol, found 228.0789 g/mol.  
 1H-NMR – R-enantiomer (600 MHz, D2O) δ 2.12 (s, 3H), 2.77 (s, 3H), 3.24 (dd, J = 
13.0, 3.3 Hz, 1H), 3.32 (dd, J = 13.0, 3.3 Hz, 1H), 6.98 (d, J = 8.6, 2H), 7.32 (d, J = 
8.6 Hz, 2H). 
 1H-NMR – S-enantiomer (600 MHz, D2O) δ 2.12 (s, 3H), 2.77 (s, 3H), 3.24 (dd, J = 
13.0, 3.3 Hz, 1H), 3.31 (dd, J = 13.0, 3.3 Hz, 1H), 6.98 (d, J = 8.6, 2H), 7.32 (d, J = 
8.6 Hz, 2H). 
 
3.2.2.3 Mass Spectrometry analysis  
The purity and accurate mass of the synthesized CpDA and the R- and S-enantiomers of 
CpDA were determined by using an ACQUITY Ultra Performance Liquid Chromatography 
(UPLC)/Q-ToF ESI-MS system equipped with an electrospray ionisation (ESI) source, which 
was operated in positive ion mode. CpDA and the R- and S-enantiomers of CpDA (1 mg/mL) 
dissolved in deionised water (Milli-QTM water purification system) and were separated on an 
Acquity UPLC® BEH C18 column (100 x 2.1mm) (Waters Corp, Milford, USA). The sample 
(5 µL) was injected onto the column and eluted at a flow rate of 0.3 mL/min over a period of 
10 minutes. Deionised water, containing 0.1% formic acid, was used as the Solvent A, 
whereas acetonitrile, containing 0.1% formic acid, was used as Solvent B. The gradient 
conditions for the chromatographic separation are listed in Table 2.  
  
Stellenbosch University  https://scholar.sun.ac.za
 
 
40 
 
Table 2. Chromatographic elution gradient of CpDA separated on an UPLC/Q-ToF/ ESI-MS system  
 Time 
(minutes) 
Flow 
(mL/min) 
%Solvent A 
Deionised water, 
0.1% formic acid 
% Solvent B 
Acetonitrile, 0.1% 
formic acid 
Curve 
1 Initial 0.300 98.0 2.0 6 
2 0.50 0.300 98.0 2.0 6 
3 7.00 0.300 20.0 80.0 6 
4 8.00 0.300 1.0 99.0 6 
5 8.10 0.300 98.0 2.0 6 
6 10.00 0.300 98.0 2.0 6 
 
The instrument setup for the separation was as follows: Capillary voltage, 2.50 kV; cone 
voltage, 15 V; extraction cone, 4 V; source temperature, 120 °C; desolvation temperature, 
275°C; source gas flow, 50 L/h; and desolvation gas flow, 650 L/h. MassLynx 4.1 software 
was used to analyse the data obtained. The ESI-MS was performed by Mr M. Taylor or Dr M. 
Stander at the Central Analytic Facilities situated in Stellenbosch University.  
3.2.2.4  Nuclear magnetic resonance – analysis 
NMR spectroscopy was performed under the supervision of Dr J. Brandt from the Central 
Analytic Facility (CAF) at Stellenbosch University. 1H-NMR and 13C-NMR analyses were 
performed on a Varian Unity INOVA 600 MHz spectrometer equipped with a 5-mm probe, 
operating at 25ºC. Deuterium oxide (D2O) was used as the solvent. 1H-NMR and 13C-NMR 
spectra of CpDA (20 mg) were recorded by using 16 scans, whereas the 1H-NMR spectra of 
the R-enantiomer (10 mg) and the S-enantiomer (4 mg) were recorded by using 32 and 128 
scans, respectively. The raw NMR data were processed using MestReNova software, version 
6.0.2.  
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3.2.2.5 Preparation of a cytochrome P450-containing mitochondrial acetone 
powder from ovine adrenals 
Cytochrome P450-enriched adrenal mitochondrial acetone powder from ovine adrenals was 
prepared as previously published (87). Fresh ovine adrenals were collected from a local 
abattoir and immediately stored on ice. All procedures were conducted at 4°C. The capsules 
and connective tissue of the frozen adrenals were removed and washed with a 0.15 M KCl 
solution (pH 7.4). The decapsulated adrenals (100 g) were homogenised with a Waring-
Blendor in 450 mL of Buffer A (10 mM Tris-HCl buffer, containing 1 mM EDTA and 0.25 M 
sucrose, pH 7.4). The adrenal homogenate was further homogenised with a Potter-Elvejhem 
glass homogeniser and the resulting homogenate centrifuged at 1000 x g for 20 minutes. The 
pellet, containing the extracellular debris and fat was discarded whilst the supernatant was 
retained. The supernatant was centrifuged at 12 000 x g for 15 minute, to yield the cytochrome 
P450-enriched mitochondrial pellet. The pellet was washed three times by resuspending and 
homogenising it once in 450 mL of Buffer B (10 mM Tris-HCl buffer, containing 1 mM EDTA, 
0.15 M KCl, pH 7.4), and twice in 200 mL of Buffer C (10 mM Tris-HCl buffer, containing 1mM 
EDTA, 0.25 M sucrose and 1% (m/v) BSA; pH 7.4). After every wash step, a centrifugation 
step was carried out for 15 minute at 12 000 x g. The mitochondrial pellet was frozen with 
liquid nitrogen and lyophilized overnight. The dried pellet (6.8 g) was resuspended in 100 mL 
dry acetone and homogenised with the Potter-Elvejhem glass homogeniser. The homogenate 
was subsequently centrifuged for 15 minutes at 12 000 x g. The supernatant was decanted 
and the mitochondrial acetone pellet (6.2 g) lyophilized overnight. The lyophilized powder was 
stored at -20°C until further use as a source of cytochrome P450 for the investigation of 
enzyme-substrate and enzyme-inhibitor interactions. 
3.2.2.6  Protein determination assay 
The protein concentration of the crude mitochondrial powder and purified CYP11B1 were 
determined according to the instruction manual of the Pierce bicinchoninic acid (BCA) Protein 
Assay Kit. A standard protein series was prepared by making a triplicate serial dilution (ranging 
from 0 µg/mL to 2000 µg/mL) of a 2 mg/mL bovine albumin serum (BSA) standard that was 
provided in the kit. Ten µL of the BSA protein standard and the mitochondrial protein samples 
were pipetted in triplicate into a 96-well micro-titre plate. A BCA working reagent was prepared 
by mixing Reagent A and Reagent B in a 50:1 ratio. Thereafter, 200 µL of the BCA working 
reagent was pipetted, with a multi-channel pipette, into the respective wells containing either 
the BSA protein standards or the mitochondrial sample. The micro-titre plate was 
subsequently incubated for 30 minutes at 37°C, followed by measuring the absorbance at 
560 nm on a Spark™ 10M multimode microplate reader. A standard curve was generated 
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from the absorbance values obtained from the protein standards and was used to determine 
the protein concentration of the samples. 
3.2.2.7  Cytochrome P450 activity assay – (CO-induced difference 
spectrum) 
The cytochrome P450 content of the crude cytochrome P450-containing mitochondrial 
acetone powder was determined spectrophotometrically as  previously described (16). The 
mitochondrial powder (2 mg/mL) was resuspended in phosphate buffer (0.1 M, pH 7.4), 
containing 10% ethylene glycol (10% m/v). The mitochondrial preparation was homogenised 
with a Potter Elvejhem homogeniser. The resulting homogenate was sonicated for 5 min at 60 
Watts. To prevent overheating of the mitochondrial sonicate, one minute intervals were 
included between each consecutive minute of sonication. CO was bubbled through the 
mitochondrial sonicate to saturate the binding sites of the heme iron. Equal volumes (1.5 mL) 
of the saturated mitochondrial sonicate were subsequently divided into two optically matched 
1.5 mL quartz cuvettes. A corrected baseline was first recorded between 400-500 nm. 
Crystalized sodium dithionite (1 – 2 mg) was used to reduce the heme-iron from the ferric to 
the ferrous state, which was added to the sample cuvette and the contents inverted. A 
difference spectrum was recorded between 400 - 500 nm. The cytochrome P450 content was 
calculated using an wavelength at 450 nm, an extinction coefficient of 91 cm-1mM-1 and a path 
length of 1 cm (16).  
3.2.2.8  Difference spectra  
Difference spectra were recorded at 25°C in 1.5 mL optically matched quartz cuvettes. All 
spectral assays were recorded in phosphate buffer (0.1 M, pH 7.4), containing 10% ethylene 
glycol (10% m/v). The cytochrome P450 concentration for all difference spectra was 
0.686 nmol P450/mg protein. The influence of an inhibitor was determined as previously 
published (87). For all spectral assays DOC was dissolved in ethanol, CpDA and R- and S-
enantiomers in dH2O. 
3.2.2.8.1  Spectral assay A: DOC-induced difference spectrum 
A substrate-induced difference spectrum of the crude mitochondrial powder was obtained as 
follows: Mitochondrial powder (2 mg/mL), suspended in phosphate buffer, was homogenised 
and the resulting homogenate sonicated for 5 minutes, with one minute intervals. The 
mitochondrial sonicate (3480 µL) was mixed with phosphate buffer (20 µL) to obtain a final 
mitochondrial volume of 3500 µL. An equal volume (1496 µL) of the mitochondrial 
enzyme/buffer preparation was pipetted into two optically matched cuvettes and a corrected 
baseline was recorded between 360-500 nm. DOC (3.2 µM, 4 µL), was added to the sample 
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cuvette and an equal volume of absolute ethanol to the reference cuvette. The content of both 
cuvettes were inverted gently and a difference spectrum recorded between 360-500 nm.  
The influence of the inhibitor on the substrate-induced difference spectrum was determined 
by replacing the phosphate buffer with the inhibitor, prior to the division into the optically 
matched quart cuvettes.  
The influence of the inhibitor on the substrate-induced difference spectrum was indicated by 
a decrease in amplitude, i.e. decreased maximum absorbance at 390 nm and an increase in 
minimum absorbance at 420 nm. The percentage inhibition was calculated by using the 
following equation:  
 Enzyme/Buffer: (Abs390nm - Abs420 nm) = x 
 Enzyme/Inhibitor: (Abs390nm - Abs420 nm) = y 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100 − ((
𝑦
𝑥
) ∗ 100)                  𝑬𝒒. 𝟏 
3.2.2.8.2  Spectral assay B: Inhibitor-induced difference spectrum 
The inhibitor-induced difference spectrum of the crude mitochondrial powder was prepared in 
the same manner as described for the substrate induced difference spectrum, prior to the 
addition of buffer/inhibitor to the mitochondrial sonicate. Equal volumes (1496 µL) of the 
mitochondrial sonicate were added to both the reference and sample cuvettes and a corrected 
baseline was recorded between 360-500 +nm. After the baseline correction, 4 µL of inhibitor 
(200 µM) was added to the sample cuvette and an equal volume of dH2O was added to the 
reference cuvette. The contents of both cuvettes were inverted gently and a difference 
spectrum recorded between 360-500 nm. 
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3.3 Results and discussion 
The present study includes the synthesis of a racemic mixture of CpDA and the separation of 
the R- and S-enantiomers of CpDA. Before the enantiomers of CpDA were separated, MS and 
NMR analysis were performed to determine the purity, the accurate mass and structure of the 
synthesized product. In addition, the spectroscopic properties of partially purified CYP11B1 
from ovine adrenals were used to establish whether CpDA was biologically active. As the 
enantiomers of CpDA had, up until the present study, not been separated, the R- and 
S-enantiomers were also subjected to MS and NMR analysis for accurate mass and structure 
elucidation. To establish whether the enantiomers were biologically active, spectral assays 
were performed and the results compared to the racemic mixture of CpDA. 
3.3.1  Synthesis of CpDA 
Acetylation of synephrine with acetyl chloride in glacial acid gave rise to a racemic mixture of 
CpDA. However, it must be emphasized that CpDA readily cyclises to its inactive form (Figure 
27) when exposed to light and oxygen, and converts back to synephrine when it is left at room 
temperature for an extended period of time. Therefore, precautionary steps were taken when 
working with CpDA, such as working in the dark and storing it at -80°C. The purity and structure 
were verified by MS and NMR analysis and the biological activity tested by using the spectral 
properties of CYP11B1 from ovine adrenals. 
3.3.1.1 Mass spectrometry analyses of CpDA 
The purity and accurate molecular weight of the newly synthesised CpDA was analysed using 
Q-ToF/ESI-MS. As shown in Figure 27, three distinct peaks were detected at approximately 
2.57, 3.02 and 4.60 minutes. Each peak was further analysed and the results are shown in 
Figure 28, Figure 29 and Figure 30, respectively. 
The ESI-MS spectrum of peak one (at 2.57 minutes) (Figure 28) shows a [M+H]+ peak at (m/z) 
at 192 and 210, respectively. The first molecular ion and its fragmentation pattern corresponds 
to formation of 2-(4-acetoxyphenyl)-1-methylaziridine ([M+H]+ =192), whereas the second 
molecular ion corresponds to 2-(4-acetoxyphenyl)-2-hydroxy-N-methylethanamine ([M+H]+ 
=210) the structure depicted in the spectrum. 
Figure 29 displays the ESI-MS spectrum from peak two (at 3.02 minutes). This spectrum 
displays a [M+H]+ peak at (m/z) at 192, 228 and 252, respectively. The fragmentation pattern 
of the molecular ion ([M+H]+=192) is consistent with the cyclisation of CpDA ([M+H]+=228) to 
the corresponding aziridine precursor (2-(4-acetoxyphenyl)-1-methylaziridine). The [M+H]+ 
peak at 252 could not be identified, it is possibly an impurity. 
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ESI-MS analysis of peak three (Figure 30) shows various peaks with molecular ions at (m/z) 
at 192, 234, 294, 316 and 332, respectively. The molecular ions ([M+H]+=192) and 
([M+H]+=294) were identified as 2-(4-acetoxyphenyl)-1-methylaziridine and acetylated 
synephrine, respectively. The structure of the acetylated synephrine is depicted in the 
spectrum. The remainder of the peaks could, however, not be identified. 
Q-ToF/ESI-MS analysis revealed that the synthesized product was indeed CpDA. However, 
CpDA was not completely pure as the fragmentation patterns revealed the presence of 2-(4-
acetoxyphenyl)-2-hydroxy-N-methylethanamine, acetylated synephrine and other unidentified 
impurities within the sample. Even though CpDA (228.0764 g/mol) is a more stable analog 
than the active compounds from the shrub, under the instrumental setup of the 
UPLC/Q-ToF MS, the Cl- (good leaving group) leaves as the highly reactive aziridine ring 
forms (biologically inactive form of CpDA) with a molecule weight at 192.1008 g/mol.  
It would have been possible to isolate peak 2 using HPLC. However, as CpDA is already labile 
under standard laboratory conditions, subjecting it to an additional HPLC step posed further 
risks for it to cyclise to its inactive form. It was, therefore, decided to use the synthesised 
mixture of CpDA as is for the separation of the enantiomers. 
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Peak 1 Peak 2 Peak 3 
Figure 27. Q-ToF MS of (1 mg/mL) CpDA prepared in deionised water. 
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 Figure 28. ESI-MS spectrum of peak one at 2.57 minutes of the Q-ToF MS analysis of synthesized CpDA. 
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 Figure 29. ESI-MS spectrum of peak two at 3.02 minutes of the Q-ToF MS analysis of synthesized CpDA. 
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Figure 30. ESI-MS spectrum of peak three at 4.60 minutes of the Q-ToF MS analysis of synthesized CpDA. 
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3.3.3.2 NMR analysis of synthesised CpDA  
The 1H-NMR and 13C-NMR analyses of the synthesized racemic mixture of CpDA are shown 
in Figure 31 and Figure 32, respectively. As shown in the 1H-NMR spectrum, the three 
protons of the -CH3 group (labelled a and b in the spectrum) are represented as a single peak 
at 2.38 ppm and 2.84, respectively. The two protons of the -CH2 group (labelled as c) are 
represented as a doublet of doublets (dd) at 3.65 and 3.77, respectively. The proton at position 
f should be a triplet, yet the results revealed a dd at 5.44 ppm. Furthermore, the two protons 
in the benzene ring (depicted as d) represents a doublet at 7.26 ppm. Similarly, the two 
protons (labelled as e) are also denoted as a doublet at 7.63 ppm. The amino group (-NH2), 
however, should have a single peak at approximately 7 ppm. There is a small peak connected 
to the doublets (labelled as d) at 7.25 ppm, which could potentially represent the amino group. 
In addition, there should be nine carbon peaks on the carbon NMR spectrum, however, there 
were a total of fourteen carbon peaks. Taken together, NMR analyses confirm that the sample 
was CpDA, however it also confirms the presence of impurities in the sample. 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. 1H-NMR analysis of synthesized CpDA. 
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Figure 32. 13C-NMR analysis of synthesized CpDA. 
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3.3.3.3 Screen for biological activity of CpDA  
The effects of CpDA on the spectral properties of partially purified CYP11B1 from ovine 
adrenals were used to screen for biological activity of CpDA. The cytochrome P450 activity 
assay and the DOC/inhibitor-induced difference spectra were performed in triplicate and the 
spectral assays are presented as the mathematical mean. 
3.3.3.3.1 Cytochrome P450 activity assay 
A cytochrome P450 activity assay was performed to determine the concentration and the 
activity of cytochrome P450 enzymes in the mitochondrial preparation. The crude enzyme 
preparation was active and free from cytochrome P420 enzyme (no peak was evident at 420 
nm), as shown in Figure 33. A maximum peak at 450 nm was observed, with a deep trough 
408 nm and a smaller trough at approximately 480 nm. Therefore, the P450-enriched 
mitochondrial powder could be used to screen for biological activity of the inhibitors. The 
cytochrome P450 concentration of a 2 mg/mL mitochondrial preparation was 0.686 nmol 
P450/ mg protein.  
Figure 33. CO-induced difference spectrum of a crude mitochondrial-acetone preparation, 2 mg/mL, in 0.1 M phosphate 
buffer, containing 10% ethylene glycol. [P450], 0.686 nmol P450/mg protein. 
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3.3.3.3.2 Difference spectra 
The influence of various concentrations of CpDA (ranging from 250 µM, 500 µM, 750 µM and 
1000 µM), dissolved in dH2O, is shown in Figure 34, and the ability of CpDA to induce a 
difference spectrum on its own is shown in Figure 35. 
The different concentrations (250 µM – 1000 µM) of CpDA inhibited the Type I DOC-induced 
difference spectra in a concentration dependent manner as a decrease shift in absorbance 
maxima and an increase shift of absorbance minima were detected at 420 and 390, 
respectively. The different concentrations of CpDA, 250 µM, 500 µM, 750 µM and 1000 µM, 
inhibited the Type I difference spectra by 16.85%, 30.84%, 50.30% and 64.53%, respectively. 
Furthermore, CpDA (200 µM) induced a Type II difference spectrum on its own with an 
absorbance minimum at 412 nm and maximum at 430 nm.  
 
Figure 34. Influence of CpDA on the DOC-induced difference spectrum of a mitochondrial suspension, 2 mg/mL, 
in 0.1 M phosphate buffer, containing 10% ethylene glycol. [P450], 0.686 nmol P450/mg protein; [DOC], 
3.21 µM; % inhibition of CpDA at 250 µM, 16.85%; 500 µM, 30.84%; 750 µM, 50,30%; and 1000 µM, 64.53%.  
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The results obtained from these spectral assays confirm that CpDA is biologically active as it 
inhibited the binding of DOC to partially purified CYP11B1 and it stabilized the low spin state 
of the iron in the absence of substrate. These results were comparable with work previously 
published (27, 28). The results furthermore confirmed that the bioactivity of the racemic 
mixture of CpDA could be used to assess the activity of the individual enantiomers of the R- 
and S-enantiomers of CpDA. 
3.3.3.3.3 Screen for biological activity of synephrine and tartaric acid 
As synephrine is the precursor of CpDA and tartaric acid is used as the resolving agent during 
the chiral resolution of the R- and S-enantiomer of CpDA, spectral assays were performed to 
determine whether these compounds could potentially influence the results. As shown in 
Figure 36 A synephrine (500 µM) and tartaric acid (500 µM) did not inhibit the Type I DOC-
induced difference spectrum. It did, however, appear that synephrine (200 µM) in Figure 36 
B induced a highly distorted Type II difference spectrum on its own as a minimum absorbance 
was detected at 419 nm and an absorbance maximum was detected at ± 446 nm. As 
synephrine is the precursor of CpDA it is possible for synephrine to stabilize the low spin state 
of the iron and still remain biologically inactive. Tartaric acid (200 µM), however, did not induce 
a Type II difference spectrum as no definite absorbance maximum or minimum were detected. 
Figure 35. Type II-induced difference spectrum of CpDA (200 µM). [P450], 0.686 nmol P450/mg protein. 
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Taken together, these results indicate that neither synephrine nor tartaric acid interferes with 
the binding of DOC to CYP11B1, therefore these compounds would not influence the results.  
 
 
 
 
 
 
 
 
 
 
 
  
A 
B 
Figure 36. Screen for biological activity of synephrine and tartaric acid. (A). Influence of synephrine (500 µM) 
and tartaric acid (500 µM) on the DOC-induced difference spectrum of a mitochondrial suspension, 2 mg/mL, in 
0.1 M phosphate buffer, containing 10% ethylene glycol. [P450], 0.686 nmol P450/mg protein; [DOC] = 3.21 µM; 
no inhibition was observed. (B) Type II-induced difference spectrum of synephrine (200 µM) and tartaric acid 
(200 µM). [P450], 0.686 nmol P450/mg protein. 
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3.3.2 Separation of the R- and S-enantiomers of CpDA 
Diastereomeric salt crystallization was used in an attempt to separate the R- and 
S-enantiomers of CpDA. This approach involved mixing a racemic mixture of CpDA with 
optically pure L-(+)-tartaric acid to produce diastereomeric salts, which were separated by 
selective crystallization using methanol as solvent. The salts were converted to the pure 
enantiomers by treatment with HCl. The change in pH protonated the tartaric acid, making it 
less soluble in the acidic solution, which allowed extraction with ether.  
The ratio of tartaric acid to 1-phenylethylamine in Ault’s experiment (86) was down-scaled in 
this study to determine whether this approach could be used to separate the enantiomers. 
Due to the labile nature of CpDA, precautions had to be implemented, which involved working 
in the dark in an acidic environment with minimum exposure to oxygen, to prevent the 
cyclisation of the open-ring aziridine structure of CpDA. 
On a micro-scale, this approach was suitable for separating the enantiomers. However, 
difficulties were experienced when applying the protocol to a preparative large scale 
preparation. 
3.3.2.1 Mass spectrometry of the R- and S-enantiomers of CpDA 
An overlay of the Q-ToF MS analysis of the R- and S-enantiomers of CpDA are shown in 
Figure 37. As depicted in the overlay of the total ion chromatogram using MS of the R- and 
S-enantiomers, five major peaks were seen for the R-enantiomer at 1.18, 2.17, 2.54, 2.93 and 
3.44 minutes and for the S-enantiomer at 1.18, 2.23, 2.54, 2.95 and 3.44 minutes. Each 
respective peak of both the R- and S-enantiomers was further analysed and the ESI-MS 
results are shown in Figure 38, Figure 39 and Figure 40. 
Figure 38 (A and B) represents the ESI-MS of the R- and S-enantiomers at 1.18 minutes 
whereas Figure 38 (C and D) depicts that of the R- and S-enantiomers at 2.17 and 2.23 
minutes, respectively.  
 The results from Figure 38 (A and B) shows a [M+H]+ peak at (m/z) at 150 and 168, 
respectively. Tartaric acid also has a molecular mass of 150.087 g/mol. However, as 
ESI-MS is performed in positive mode, and tartaric acid is fully protonated, it is not 
possible to see tartaric acid in the mass spectrum. The [M+H]+ peak at (m/z) = 150, 
therefore, more likely represents 2-(4-hydroxyphenyl)-1-methylaziridine (structure 
depicted in Figure 38 A), whereas the peak at (m/z) =168 is unequivocally identified 
as synephrine.  
 The results from Figure 38 (C and D) show a [M+H]+ peak at (m/z) at 150 and 182, 
respectively. Similarly, to the results shown in Figure 38 (A and B), the [M+H]+ peak 
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at (m/z) = 150, represents 2-(4-hydroxyphenyl)-1-methylaziridine. The [M+H]+  peak at 
(m/z) = 182 could not be identified. However, it is possible that the molecular ion and 
its fragmentation pattern is the result of contamination. It was interesting to see that 
the S-enantiomer had a bigger peak at 2.20 minutes in the time-of-flight mass spectrum 
(Figure 37), suggesting that the S-enantiomer is more labile than the R-enantiomer as 
more of the S-enantiomer cyclizes into the 2-(4-hydroxyphenyl)-1-methylaziridine than 
the R-enantiomer. 
Figure 39 (A and B) represents the ESI-MS of the R- and S-enantiomers at 2.54 minutes 
whereas Figure 39 (C and D) denotes ESI-MS of the R- and S-enantiomers at 2.93 and 2.95 
minutes, respectively.  
 Three major peaks were seen in Figure 39 (A and B) at a (m/z) of 150, 192 and 210, 
which were representative of 2-(4-hydroxyphenyl)-1-methylaziridine, 
2-(4-acetoxyphenyl)-1-methylaziridine (inactive form of CpDA) and 
2-(4-acetoxyphenyl)-2-hydroxy-N-methylethanamine, respectively. In contrast to the 
mass spectrum of the R-enantiomer in Figure 39 (A), the mass spectrum of the 
S-enantiomer of Figure 39 (B) had more fragmentation, suggesting that the 
S-enantiomer contained more impurities than the R-enantiomer.  
 The results from Figure 39 (C and D) show [M+H]+ peaks at (m/z) at 150, 192, 228 
and 252 which denotes 2-(4-hydroxyphenyl)-1-methylaziridne, 2-(4-acetoxyphenyl)-1-
methylaziridine, CpDA and an unidentified compound, respectively.  
Figure 40 (A and B) represents the ESI-MS of the R- and S-enantiomers at 3.44 minutes.  
 Three major [M+H]+ peaks were seen at a (m/z) of 150, 192 and 224. The 
fragmentation pattern of (m/z) = 150 and 192 is consistent with 2-(4-hydroxyphenyl)-
1-methylaziridine and 2-(4-acetoxyphenyl)-1-methylaziridine. However, the [M+H]+ 
peak at (m/z) =224 could not be identified to a specific compound, and therefore it is 
possible that this fragment is an impurity. 
Taken together, these results suggest the successful separation of the R- and S-enantiomers 
of CpDA as comparable mass spectra were seen in both the Q-ToF MS (Figure 37) and the 
ESI-MS analysis (Figure 38, Figure 39 and Figure 40). However, the ESI-MS analysis 
suggests that the R- and S-enantiomer cyclizes into 2-(4-hydroxyphenyl)-1-methylaziridine 
and the inactive form of CpDA, suggesting that the separation of the enantiomers influences 
the stability and therefore the activity of the R- and S-enantiomers. 
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Figure 37.Q-ToF MS of the R- and S-enantiomers (1 mg/mL) of CpDA prepared in deionised water. 
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A B 
C D 
Figure 38. ESI-MS spectra of the Q-ToF MS spectrum of CpDA enantiomers. (A) R-enantiomer and (B) S-enantiomer at 1.18 minutes (Peak 1); (C) R-enantiomer at 2.17 minutes 
and (D) S-enantiomer at 2.23 minutes (Peak 2). 
2-(4-hydroxyphenyl)-1-methylaziridine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
R- enantiomer at 1.18 minutes (Peak 1) S- enantiomer at 1.18 minutes (Peak 1) 
R- enantiomer at 2.17 minutes (Peak 2) S- enantiomer at 2.23 minutes (Peak 2) 
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Figure 39. ESI-MS spectra of the Q-ToF MS spectrum of CpDA enantiomers. (A) R-enantiomer and (B) S-enantiomer at 2.54 minutes (Peak 3); (C) R-enantiomer at 2.93 minutes and 
(D) S-enantiomer at 2.95 minutes (Peak 4). 
  
R- enantiomer at 2.54 minutes (Peak 3) S- enantiomer at 2.54 minutes (Peak 3) 
R- enantiomer at 2.93 minutes (Peak 4) S- enantiomer at 2.95 minutes (Peak 4) 
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R- enantiomer at 3.44 minutes (Peak 5) S- enantiomer at 3.44 minutes (Peak 5) B A 
Figure 40. ESI-MS spectra of the Q-ToF MS spectrum of CpDA enantiomers. (A) R-enantiomer and (B) S-enantiomer at 3.44 minutes (Peak 5); 
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3.3.2.2 NMR analysis of the R- and S-enantiomers of CpDA 
As enantiomers are structurally identical, they will have a similar proton and carbon NMR 
spectrum. However, due to the low yield of the S-enantiomer, only a proton spectrum of the 
R- and S-enantiomers were completed. The proton spectrum of the R- and S-enantiomers, as 
shown in Figure 41, are stacked above each other to demonstrate the similarity in the 1H-NMR 
analysis of the enantiomers. There are, however, some differences in the proton spectra as 
the R-enantiomer has an additional proton peak at approximately 3.4 and 3.7 ppm, whilst the 
S-enantiomer has an additional proton peak at 2.1 ppm. Because the racemic mixture of CpDA 
already contained impurities, it was expected that the enantiomers would also contain some 
impurities. The proton spectra of the R- and S-enantiomers of CpDA nevertheless show 
significant similarity, indicating that they are indeed the R- and S-enantiomers of CpDA. 
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Figure 41. Stacked 1H-NMR spectra of the R- and S-enantiomers of CpDA. 
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3.3.2.3 Biological activity of the R- and S-enantiomers of CpDA 
Spectral assay A (DOC-induced difference spectrum) and Spectral assay B (Inhibitor-induced 
difference spectrum) were used to determine the biological activity of the R- and 
S-enantiomers. The influence of the R- and S-enantiomers on the DOC-induced difference 
spectrum is shown in Figure 42 A. As CpDA (750 µM) inhibited ± 50% on the Type I-induced 
difference spectrum (Figure 34), this concentration was chosen as the standard to compare 
the inhibitory potential of the R-enantiomer and the S-enantiomer.  
As shown in Figure 42 A, the three test compounds inhibited the DOC-induced Type I 
difference spectrum, with the inhibition of CpDA (750 µM), being 51.05% and the R- and 
S-enantiomers (750 µM) 18.96% and 31.54%, respectively. 
Furthermore, both the R-enantiomer (200 µM) and the S-enantiomer (200 µM) had the ability 
to induce a Type II difference spectrum (Figure 42 B).  It is, however, interesting to note that 
the R- and S-enantiomers induced different Type II difference spectra. The R-enantiomer had 
an absorbance minimum and maximum at approximately 412 nm and 430 nm, respectively, 
which was comparable with the Type II difference spectrum induced by CpDA (Figure 35). 
The S-enantiomer, however, induced an absorbance minimum at 402 nm and an absorbance 
maximum at 440 nm. 
Taken together, these results clearly show that the R- and S-enantiomers are biologically 
active, as they inhibited the DOC-induced Type I difference spectrum and induced a Type II 
difference spectrum in the absence of substrate. It was interesting to note the S-enantiomer 
was biologically more active than the R-enantiomer, even though there were more impurities 
in the S-enantiomer. In addition, the Type II difference spectrum induced by the S-enantiomer 
was different to that of both CpDA and the R-enantiomer, suggesting that the enantiomers 
interact differently with the enzymes in the P450-enriched mitochondrial preparation. The 
mechanism of action of the R- and S-enantiomers of CpDA could, however, only be explained 
by investigating the effects of each enantiomer with purified CYP11B1 from ovine adrenals.
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Figure 42. (A) Influence of CpDA (750 µM) and the R-enantiomer (750 µM) and the S-enantiomer (750 µM) on the 
DOC-induced difference spectrum of a mitochondrial suspension, 2 mg/mL, in 0.1 M phosphate buffer, containing 10% 
ethylene glycol. [P450], 0.686 nmol/mg protein; [DOC], .3.21 µM; % inhibition of CpDA and the R- and S-enantiomers 
of CpDA was 51.05%,18.96 % and 31.54%, respectively (B) Type II-induced difference spectrum of the R-enantiomer 
in red (200 µM) and S-enantiomer in blue (200 µM) of CpDA. [P450], 0.686 nmol P450/mg protein. 
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3.4 Conclusion 
The work described in this chapter included the synthesis of a racemic mixture of CpDA, the 
separation of the R- and S-enantiomers of the racemic mixture of CpDA and the determination 
of the biological activity of the racemic mixture and each enantiomer.  
Q-ToF/ESI-MS, 1H-NMR, 13C-NMR and biological studies confirmed the successful synthesis 
of a racemic mixture of CpDA. Data obtained by MS and NMR, however, showed that there 
were impurities in the synthesized sample, which were attributed to formation of 2-(4-
acetoxyphenyl)-2-hydroxy-N-methylethanamine and tri-acetylated synephrine. In addition, MS 
also indicated that a large portion of the ring-opened form of CpDA cyclises into the inactive 
aziridine, demonstrating the unstable nature of CpDA. However, the conversion from the 
active to the inactive form during MS analyses could be attributed to the instrumental set up 
as a high cone voltage and source temperature may influence the structure of CpDA. Spectral 
studies with CpDA and CYP11B1 confirmed that it was biologically active. The CYP11B1 
spectral assays further confirmed that synephrine and tartaric acid were not biologically active 
and as such would therefore not influence the activity studies with the enantiomers.  
The enantiomers of CpDA were separated via diastereomeric salt crystallization by reacting it 
with an optically pure resolving agent (L-(+)-tartaric acid). A micro-separation was first carried 
in which the reaction was scaled down (± 30-fold), to assess the viability of the salt 
crystallization protocol. Although the separation of the enantiomers was successful the R- and 
S-enantiomers were not completely pure, as indicated in the LC-Q-ToF MS and NMR analysis. 
Spectral studies with a P450-containing mitochondrial powder, nevertheless showed that the 
enantiomers were biologically active even in the presence of impurities introduced in the 
separation and in the synthesis of CpDA. Interestingly, the two compounds acted differently 
in a biological environment, with the S-enantiomer inducing a greater inhibitory effect on the 
binding of DOC to CYP11B1 than the R-enantiomer. The R-enantiomer, however, induced a 
distinct Type II difference spectrum, similar to the racemic mixture of CpDA, while the 
S-enantiomer did not induce a typical difference spectrum of any kind. 
Unfortunately, due to the impurities, the optical rotation of the respective enantiomers could 
not be determined, as a pure sample (≥ 95%) is required for both a polarimeter and circular 
dichroism to produce accurate interpretations. However, as Ault used a compound (86) 
structurally similar to CpDA, it is assumed that the respective enantiomers allocated in this 
study were the R- and S-enantiomers of CpDA. 
As part of this study, it was important to scale the micro-separation protocol up to a preparative 
protocol to allow the separation and purification of the two enantiomers. It was, however, a 
tremendous challenge as LC-Q-ToF MS analyses revealed the complete conversion of the 
Stellenbosch University  https://scholar.sun.ac.za
 
 
66 
 
active form of CpDA to the inactive form. Spectral studies further confirmed that the 
enantiomers that were separated on a preparative-scale were biologically inactive. For future 
studies the diastereomeric salt crystallization for the separation of the R- and S-enantiomers 
of CpDA on a preparative scale will have to be refined and adapted in order to yield sufficient 
material to fully characterise the enantiomers. 
To conclude, CpDA was successfully synthesised and its enantiomers separated by using 
diastereomeric salt crystallization. In Chapter 4, the interaction of the enantiomers and the 
racemic mixture of CpDA with highly purified CYP11B1 will be described. 
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CHAPTER 4 
The interaction of CpDA and its enantiomers with purified 
ovine adrenal cytochrome P450 11β-hydroxylase and 
adrenal mitochondrial electron transport 
 
4.1 Introduction 
In Chapter 3, the interaction of partially purified CYP11B1 with CpDA and its enantiomers were 
described. Previous studies with purified CYP11B1 from ovine adrenals indicated that CpDA 
is a mixed inhibitor of CYP11B1, with both a competitive (Kic = 106-110 µM) and uncompetitive 
element (Kiu = 667-737 µM) (27). The fact that CpDA is a chiral compound (24, 30) can 
contribute to the mixed inhibitory effects observed. It was therefore decided to investigate the 
enzyme-substrate and enzyme-inhibitor interaction of CpDA and the R- and S-enantiomers 
with fully purified ovine CYP11B1. 
As discussed in Chapter 2, the spectral properties of cytochrome P450 enzymes are 
influenced by a range of factors, such as temperature, pH, ionic strength, the presence of a 
substrate or inhibitor, as well as the purity of the preparation. The crude mitochondrial 
preparation used in the spectral assays contained a mixture of endogenous cholesterol, 
cytochrome c, ADXR, ADX, as well as CYP11A1, CYP11B1 and CYP11B2. Even though the 
two mitochondrial enzymes are substrate specific, CYP11A1 could influence results and 
interpretations of the spectral assays. The spectral properties of CYP11B1 can also be 
influenced by the contaminating components, such as the endogenous cholesterol and the 
various cellular proteins in the crude mitochondrial extract (7, 18, 70). Spectral assays with 
purified CYP11B1 therefore provided a more comprehensive understanding of the mechanism 
of action of the R- and S-enantiomers of CpDA.  
The adrenal mitochondrial steroid hydroxylation system is dependent on a short but highly 
specific electron transport chain (79, 88). NADPH reduces ADXR which subsequently 
transfers a single electron to ADX, which in turn supplies electrons to the mitochondrial 
cytochrome P450 enzymes (7, 18, 89). It was therefore deemed necessary to also investigate 
the influence of CpDA and the R- and S-enantiomers of CpDA on the adrenal mitochondrial 
electron transport system. As purified CYP11B1 is extremely unstable, commercially available 
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cytochrome c was used in the place of CYP11B1 as the terminal electron acceptor in this 
study (7, 18, 90). 
The study described in this chapter investigated the influence of the racemic mixture as well 
as the two enantiomers of CpDA on purified ovine mitochondrial CYP11B1 using difference 
spectroscopy. The influence of the same compounds on ovine adrenal mitochondrial electron 
transport was investigated using a partially purified ADXR/ADX preparation and cytochrome c 
as terminal electron acceptor.  
4.2  Experimental  
4.2.1 Materials and reagents 
Fresh ovine adrenals were collected from Tomis Abattoir & Fresh Meats Wholesalers 
(Hermon, South Africa). Centrifugation was performed on a Beckman Coulter 
Avanti® J-E centrifuge, whilst the Beckman Optima™ L-80 XP model was used for 
ultracentrifugation. Sonication was done with a Branson B12 sonifier. Spectral assays were 
recorded on a Spark™ 10M multimode microplate reader from Tecan (Männedorf, 
Switzerland). Lyophilisation was done with a VirTis® BenchTop™ K freeze dryer from United 
Scientific (South Africa). The Pierce bicinchoninic acid (BSA) protein quantification kit was 
acquired from Thermo Fisher Scientific (Rockford Ill, USA). Polyethylene glycol (PEG) 35 000 
and the molecular sieve beads (0.3 Å) were purchased from Merck Millipore (South Africa). 
The primary antibodies, rabbit anti-sheep IgG against CYP11B1, rabbit anti-sheep IgG ADX 
and rabbit anti-sheep IgG against ADXR, were in-house antibodies part of previous projects, 
available in the cytochrome P450 laboratory. Anti-Rabbit goat IgG-peroxidase secondary 
antibody, glucose-6-phoshate, glucose-6-phoshate dehydrogenase, Phenyl-Sepharose CL-
4B resin, sodium dithionite and Tween®20 were purchased from Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA). Spectra/Por® 4 dialysis membrane tubing (MWCO, 3.5 kDa) was 
obtained from Spectrum labs (South Africa). Purification was performed using the Bio-Rad 
NGC chromatography system and fractions collected using a BioFracTM fraction collector 
(California, USA). The electrophoresis chamber, Mini-PROTEAN® Tetra Hand cast System, 
Kaleidoscope marker, Precision Plus Protein™ Kaleidoscope™ Pre-stained Protein Standard, 
and the Clarity Western™ ECL Chemiluminescent Blotting Substrate were purchased from 
Bio-Rad (California, USA). Bio-Trace NT pure nitrocellulose blotting membranes were 
purchased from Pall Life Sciences (South Africa). 
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4.2.2 Methods 
4.2.2.1 The preparation of a P450-containing mitochondrial acetone powder 
from ovine adrenals 
P450-enriched adrenal mitochondrial-acetone powder from ovine adrenals was prepared as 
described in Section 3.2.2.5 The powder was used to isolate and purify CYP11B1 and to 
isolate a partially purified ADX/ADXR preparation. 
4.2.2.2 The preparation of ADXR/ADX from ovine adrenal mitochondrial 
powder 
All steps in the isolation of  ADX and ADXR were performed at 4ºC according to a previously 
reported method (7, 14, 90). Crude mitochondrial powder (2 g) was resuspended in a 0.1 M 
Tris buffer (100 mL, pH 7.4) and sonicated on ice for 10 minutes at 60 Watts, to disrupt the 
mitochondrial membrane. One-minute interval was allocated between every minute of 
sonication to prevent overheating of the mitochondrial preparation. The mitochondrial sonicate 
was ultra-centrifuged at 150 000 x g for 100 minutes. The supernatant contained crude ADX 
and ADXR, and the pellet insoluble cytochrome P450 mitochondrial enzymes, which could be 
used to isolate pure substrate-free CYP11B1. The ADX and ADXR protein solution was 
concentrated in a protein concentrator specifically designed for this purpose (7, 91). The 
method is based on the osmotic transfer of water to a hydrophilic polymer solution, PEG 
35 000 20% (w/v), through a dialysis membrane (MWCO: 3.5 kDa). The 50 mL volume of ADX 
and ADXR protein solution (supernatant) was concentrated to 6 mL within 3 hours, without 
loss of biological activity. The concentrated ADX and ADXR solution was stable for a month 
at -80ºC. 
4.2.2.3 BCA protein determination assay 
The protein concentration of the crude mitochondrial powder and purified CYP11B1 were 
determined by following the instruction manual of the BCA Protein Assay Kit, as described in 
Section 3.2.2.6. 
4.2.2.4 Cytochrome P450 activity assay 
Cytochrome P450 activity assays were performed during each purification step of CYP11B1 
to verify that the enzyme remained active and to determine the concentration of CYP11B1 
after each purification step. Due to restricted amount of purified enzyme available, the 
cytochrome P450 activity assay had to be adapted to a 96-well micro-titre plate assay to 
preserve enzyme for further spectral assays. The total volume required to perform this assay 
was reduced from 3 mL to 300 µL. CO was bubbled through a purified CYP11B1 preparation. 
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Equal volumes (150 µL) of the CO saturated enzyme were pipetted into two separate wells of 
a 96 well micro-titre plate. One well served as the reference well and the second well as the 
sample well. A baseline was recorded between 400-500 nm. After the baseline recording, 10 
µL of sodium dithionite dissolved in deionised water (1 mg/mL) was added to the sample well 
and an equal volume of deionised water to the reference well. A difference spectrum was 
recorded between 400-500 nm. The cytochrome P450 content was calculated using the 
wavelength at 450 nm, an extinction coefficient of 91 cm-1mM-1 (16) and a path length of 
0.47983 cm on a flat bottom well plate. 
4.2.2.5  Isolation and purification of substrate bound ovine CYP11B1  
The isolation and purification of CYP11B1 from the P450-containing mitochondrial-acetone 
powder was carried out at 4°C to preserve enzyme activity. All of the isolation and purification 
buffers contained DOC, to stabilize the enzyme. The purification of CYP11B1 was modified 
from methods previously published (7, 18, 92). 
4.2.2.5.1  Isolation of CYP11B1 from a crude mitochondrial powder 
The mitochondrial acetone powder (4 g, 2376 mg protein), was resuspended in 110 mL 
standard buffer (50 mM potassium phosphate, 100 µM EDTA, 100 µM DTT, and 10 µM DOC, 
pH 7.4). The mitochondrial suspension was supplemented with Tween20 (0.3%, (v/v)), followed 
by sonication of the suspension for 30 minutes at 60 Watts on ice. One minute intervals were 
prescribed between every minute of sonication to prevent the loss of protein activity. The 
protein concentration of the sonicate was adjusted to 20 mg/mL using the standard buffer. 
CYP11B1 was extracted from the P450-enriched sonicate by the dropwise addition of 10% 
sodium cholate to yield a final concentration of 1% sodium cholate. The mixture was stirred 
for one hour and thereafter subjected to ultra-centrifugation at 105 000 x g for 104 minutes at 
4°C. The resulting supernatant was retained and fractionated with ammonium sulphate. The 
ammonium sulphate concentration required to fractionate CYP11B1 was between 0 – 32% 
saturation. The CYP11B1-containing precipitate was stirred for one minute and centrifuged at 
12 000 x g for 15 minutes at 4°C. The resulting pellet was resuspended in standard buffer, 
containing 1% sodium cholate and 1 M KCl (20 mL) pH 7.4. Alumina γ C gel 
(380 mg/g mitochondrial pellet) was added to the suspension and stirred for 30 minutes on 
ice. After the 30 minutes, the Alumina γ C was removed by centrifugation at 12 000 x g for 10 
minutes at 4°C. The resulting supernatant (20 mL) was retained and dialyzed overnight against 
2 L standard buffer. 
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4.2.2.5.2  Purification of CYP11B1 
The dialysate which contained precipitated CYP11B1, was collected and subjected to 
ultra-centrifugation at 100 000 x g for 100 minutes at 4°C. The resulting pellet was 
resuspended in 8 mL equilibration buffer (standard buffer containing 0.7 % sodium cholate 
and 200 mM KCl, pH7.4) and stirred for 10 minutes to yield a homogenous sample. As the 
volume of the sample was small and too sensitive to filter, it was centrifuged at 3000 x g for 5 
minutes at 4°C. The supernatant was decanted and used to purify CYP11B1 using HIC on a 
Phenyl-Sepharose CL-4B column. Phenyl-Sepharose CL-4B resin was prepared according to 
the instruction manual and packed in an 8 cm x 1 cm column1. The supernatant (7 mL) was 
applied onto the resin using a Finnigan Surveyor Auto sampler-plus fitted with a 10 mL sample 
loop. The column was equilibrated with the equilibration buffer (2 x column volume), or until a 
stable baseline was obtained. The Bio-Rad NGC chromatographic system was set to measure 
the absorbance at 280 mAU during the run, at a flow rate of 1 mL/min by using a linear 
gradient. CYP11B1 was eluted with an elution buffer (standard buffer containing 0.5 % sodium 
cholate, 500 mM KCl, 0.5 % Tween20 pH7.4). The elution profile of CYP11B1 is summarized 
in Table 3. 
Table 3. Chromatographic elution profile for CYP11B1 
 
Time 
(minutes) 
Flow 
(mL/min) 
% Washing buffer % Elution buffer 
1 0.01 1 100 0 
2 12 1 0 100 
3 62 1 100 100 
4 72 1 100 0 
5 90 1 0 0 
 
Cytochrome P450 activity assays were performed on all the fractions and only the active 
fractions were collected (20 mL) and re-concentrated with ammonium sulphate (0-32%) for 
four hours. The precipitate was centrifuged at 12 000 x g for 10 minutes and the resulting 
pellet resuspended in 5 mL dialyzing buffer (standard buffer, containing 0.3 % sodium cholate, 
0.3 % Tween20, pH 7.4). The purified substrate-bound CYP11B1 was dialyzed against 1 L 
dialyzing buffer for 5 hours and subsequently used to prepare a substrate-free CYP11B1 
                                               
 
1 This commercially available resin replaced the aniline-Sepharose CL-4B resin previously used for the 
purification of CYP11B1. Aniline Sepharose CL-4B is not commercially available and had to be prepared 
using highly toxic cyanogen bromide (CNBr) to activate Sepharose CL-4B prior to aniline coupling (92). 
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preparation. The substrate-bound CYP11B1 preparation (5 mL) contained 11.563 nmol 
P450/mg protein. 
4.2.2.6 SDS-PAGE analyses of purified CYP11B1 and ADX/ADXR 
SDS-PAGE analyses of the purified substrate-bound CYP11B1 and the crude ADX/ADXR 
preparation were performed as previously published (93). Briefly, protein samples (25 µL) 
were electrophoresed using 12% polyacrylamide gels for 40 minutes at 4°C and 200 V. 
Precision Plus Protein™ Kaleidoscope™ Standard marker (10-250 kDa) was used to monitor 
protein separation. After the electrophoretic separation of the protein samples, the individual 
gels were placed in separate holders and stained for 60 minutes with Coomassie Brilliant Blue 
R- 250 staining solution (3 mM Coomassie R-250, in 10% acetic acid and 45% methanol). The 
staining solution was decanted and the gels placed in 30 mL destain 1 solution ((50% (v/v) 
methanol, 10% (v/v) acetic acid) for 60 minutes. After 60 minutes destain 1 solution was 
replaced with 30 mL destain 2 solution (20% (v/v) methanol, 7% (v/v) acetic acid), overnight 
after which the protein bands were visualised and photographed. 
4.2.2.7 Western Blot analysis of CYP11B1 and ADX/ADXR 
Western blot analyses were performed after the separated protein samples were transferred 
from the SDS-PAGE gels to Bio-Trace NT pure nitrocellulose blotting membranes (93). After 
the 90-minute transfer step at 4°C, 110 V, the surface of the nitrocellulose membranes was 
blocked, by gently agitating the membranes with 20 mL casein buffer (10 mM Tris, pH 7.6, 
0.15 M NaCl, 0.5% (m/v) casein) for 30 minutes at 37°C. Thereafter, the casein buffer was 
replaced with fresh casein buffer (20 mL) and the membrane incubated with the respective 
primary anti-bodies for 60 minutes at 37°C. Rabbit anti-sheep against CYP11B1 (1:4000), 
rabbit anti-sheep against adrenodoxin (1:6000) and rabbit anti-sheep against ADXR (1:6000) 
were used as the primary antibodies for the detection of CYP11B1 and ADX/ADXR, 
respectively. After the 60 minutes, the casein buffer was decanted and the membranes 
washed 4 times with a 0.5% Tween20-PBS solution. Each washing step was carried out for 
four minutes. Each membrane was subsequently incubated with goat-anti-rabbit secondary 
antibody (1:20 000 in casein buffer) for 60 minutes at 37°C after which the membranes were 
washed 4 times as described. Each membrane was incubated with a 1:1 ratio of Pierce ECL 
Western Blotting chemiluminescent substrate reagent for one minute. The chemiluminescent 
substrate reagent was decanted and the individual blots developed using Fuji medical X-ray 
film (Fuji Photo Film Co.) with an exposure time ranging from 5-10 seconds. 
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4.2.2.8 Preparation of substrate-free CYP11B1  
As previously mentioned, CYP11B1 is extremely unstable when released from its membrane 
and substrate and readily converts to its inactive P420 form within one hour. Therefore, during 
the purification, an excess of DOC is added to all buffers to stabilize the enzyme and preserve 
activity. However, the mechanism of action of the R- and S-enantiomers of CpDA can only be 
determined when the substrate is removed and the heme-iron converts back into the low-spin 
state. Therefore, substrate-free CYP11B1 was prepared with the aid of dextran coated 
charcoal (DCC) as previously described (13, 18, 26). All experimental procedures were carried 
out at 4°C. 
4.2.2.8.1 Preparation of dextran-coated charcoal (DCC) 
Dextran T70 (0.1 g) was dissolved in 200 mL Tris-buffer (10 mM, pH 8) containing EDTA 
(1 mM) and NaCl (150 mM) and stirred for 10 minutes, until a homogenous solution was 
obtained. Norit A charcoal (1 g) was added to the homogenous solution and stirred for four 
hours at 25°C. Three millilitre of the resulting DCC suspension was centrifuged at 12 000 x g 
for 10 minutes. The pellet was washed three times by resuspension in standard buffer and 
centrifugation at 12 000 x g. After the final wash, the DCC pellet was resuspended in standard 
buffer (1 mL). 
4.2.2.8.2 Preparation of substrate-free CYP11B1 with the aid of DCC 
The DCC-suspension (100 µL) was added to the purified substrate-bound CYP11B1 (1 mL). 
The resulting mixture was stirred for 15 minutes, after which the mixture was placed in a 
specially designed centrifuge tube into which a 0.45 µm filter membrane was fitted (Figure 
43). With the aid of centrifugation at 3000 x g for 3 minutes, the substrate-free enzyme mixture 
was filtered through to the sample collection chamber. To ensure that all the steroid was 
removed from the enzyme, the DCC-suspension (100 µL) was added to the filtrate, containing 
substrate-free CYP11B1, and the same process was repeated. As the substrate-free 
CYP11B1 remained active for one hour after the removal of the steroid, all spectral assays 
therefore had to be carried out within that time-frame. 
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4.2.2.9  Spectral assays 
The influence of the R- and S-enantiomers of CpDA on the spectroscopic properties of purified 
CYP11B1 was investigated using a modified previously reported method (7, 18, 87). Due to 
the limited volume of purified substrate-free CYP11B1 the spectral assays were not recorded 
on a Cary UV-100 spectrophotometer in 1.5 mL cuvettes as previously published, but on a 
Spark™ 10M multimode microplate reader (96-well micro-titre plates). As discussed in 
Chapter 2, only a specialized spectrophotometer can be used to record the difference spectra 
of turbid samples. Therefore, before any spectral assays were performed with the purified 
enzyme, this method was optimized for the microplate reader using partially purified 
CYP11B1. A similar inhibitory profile was obtained in both the Cary 100 UV spectrophotometer 
and the multimode microplate reader, therefore the modified method could be used to 
determine the mechanism of interaction of the R-and S-enantiomers of CpDA with purified 
CYP11B1. Due to the labile nature of the substrate-free enzyme, the amount needed for each 
experiment was freshly prepared prior to each experiment.  
  
 
Figure 43. Schematic representation of the specially designed centrifuge tube. The sample application chamber 
(1) is connected to a 1 mL reactivial sample collector chamber (5), screwed into one another by the membrane 
support holder (4). The 0.4 µm filter membrane (7), cut to the right size using a punch, is supported by a porous 
poly-ethylene membrane support (3) and sealed by an O-ring (2). An air vent placed at a 65°angle on the sample 
application chamber prevents air trapping in the system. Redrawn from (18). 
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4.2.2.9.1  Spectral Assay A - DOC-induced difference spectra 
The design setup for the DOC-induced difference spectrum is shown in Table 4. The buffer 
used for Well 1 and Well 2 (control) was standard buffer (without DOC). The final concentration 
of inhibitor (CpDA, and the R- and S-enantiomers of CpDA, respectively) in Well 3 and Well 4 
was 750 µM. The DOC concentration was increased from 3.21 µM to 10 µM to give a better 
response. 
Table 4. Design protocol for Spectral Assay A. 
 
Control 
A baseline was recorded between 360-500 nm for both Wells 1 and 2. Ethanol was added to 
Well 1 and the DOC solution was added to Well 2 and a spectrum recorded between 
360-500 nm for each well. After baseline correction, for both Wells 1 and 2, the absorbance 
values of the ethanol containing well (Well 1) was subtracted from the absorbance values from 
the DOC containing well (Well 2) to obtain a difference spectrum.  
Inhibitor 
The same protocol as described under control was carried for each respective inhibitor (CpDA, 
the R-enantiomer, and the S-enantiomer) in Wells 3 and 4. The percentage inhibition was 
calculated by using the equation presented in Section 3.2.2.8.1. 
  
Baseline recording 
Add substrate and 
record 
C
o
n
tr
o
l 
Well 1 196 µL purified substrate-free CYP11B1 4 µL buffer 2 µL ethanol 
Well 2 196 µL purified substrate-free CYP11B1 4 µL buffer 2 µL DOC (10 µM) 
In
h
ib
it
o
r Well 3 196 µL purified substrate-free CYP11B1 
4 µL of Inhibitor 
(750 µM) 
2 µL ethanol 
Well 4 196 µL purified substrate-free CYP11B1 
4 µL of Inhibitor 
(750 µM) 
2 µL DOC (10 µM) 
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4.2.2.9.2  Spectral Assay B – inhibitor-induced difference spectrum 
The design setup for the inhibitor-induced difference spectrum is shown in Table 5. 
Table 5 . Design protocol for Spectral Assay B 
 
A baseline was recorded between 360-500 nm for both wells for each respective inhibitor 
(CpDA, R- and S-enantiomer). Distilled water was added to the reference wells (1, 3 and 5) 
whereas the respective inhibitor was added to the sample wells (2, 4 and 6) and a spectrum 
recorded between 360-500 nm for each well. After baseline correction, for all the reference 
and sample wells of the respective inhibitors, the absorbance values of the reference wells (1, 
3 and 5) was subtracted from the absorbance values from the inhibitor containing wells (2, 4 
and 6) to obtain a difference spectrum.  
  
Baseline recording Add inhibitor and record 
C
p
D
A
 
Well 1 196 µL purified substrate-free CYP11B1 4 µL dH2O 
Well 2 196 µL purified substrate-free CYP11B1 4 µL CpDA (200 µM) 
R
-e
n
a
n
ti
o
m
e
r 
Well 3 196 µL purified substrate-free CYP11B1 4 µL dH2O 
Well 4 196 µL purified substrate-free CYP11B1 4 µL R-enantiomer (200 µM) 
S
-e
n
a
n
ti
o
m
e
r 
Well 5 196 µL purified substrate-free CYP11B1 4 µL dH2O 
Well 6 196 µL purified substrate-free CYP11B1 4 µL S-enantiomer (200 µM) 
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4.2.2.10 Influence of the CpDA and the R- and S-enantiomers on the partially 
purified ADX/ADXR electron transport system  
The activity of the crude mixture of ADX/ADXR electron transport system was determined by 
a modification of a previously published method (7, 14, 90). This method was modified to use 
a 96-well micro-titre plate instead of 2.5 mL quart cuvettes. All reagents were dissolved in a 
phosphate buffer (0.02 M, pH 7.4). In order to test the activity of the electron transport 
reductase system, cytochrome c was used as the electron acceptor. The reaction was initiated 
by the addition of NADPH (1 mM, 4 µL) to the reaction mixture. 
Reference well  
 The incubation mixture of the reference well comprised of cytochrome c (50 nmol, 
50 µL), 50 µL of a phosphate buffer (0.02 M, pH 7.4), glucose-6-phosphate (G6P) 
(1 µmol, 50 µL) and glucose-6-phosphate dehydrogenase (G6PD) (0.32 U, 50 µL).  
Sample well  
 The incubation mixture of the sample well comprised of the same incubation mixture 
except for the phosphate buffer which was replaced with the ADX/ADXR solution 
(50 µL).  
Sample well with inhibitor 
 The influence of an inhibitor on the reduction of cytochrome c was tested by adding 
5 µl of the inhibitor into the incubation mixture. The incubation mixture comprised of 
cytochrome c (50 nmol, 50 µL), 45 µL of ADX/ADXR solution, 5 µL of inhibitor with two 
concentrations (750 µM and 375 µM), G6P (1 µmol, 50 µL) and G6PD (0.32 U, 50 µL).  
After pre-incubating the reaction mixtures for 5 minutes at 25ºC, NADPH (0.04 M, 4 µL) was 
added to initiate the reaction. The total volume in each well was 204 µL. The reduction of 
cytochrome c was monitored at 550 nm. The reduction of cytochrome c was calculated by 
using an extinction coefficient of 29.5 cm-1mM-1 and a path length of 0.60561 cm (90). 
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4.3  Results and discussion 
4.3.1 Isolation and purification of purified substrate-free CYP11B1 
The present study involved the isolation and purification of substrate-free CYP11B1. The 
unique spectroscopic properties of the highly purified enzyme were used to investigate the 
influence (inhibition) of the CpDA enantiomers on the DOC-induced difference spectrum and 
their ability to bind CYP11B1 in the absence of substrate and induce a Type II difference 
spectrum (inhibitor-induced difference spectrum). The results of the spectral assay of the 
enantiomers were compared to the racemic mixture of CpDA. In the second part of this study, 
the influence of the inhibitors on the reduction of cytochrome c by the ADX/ADXR electron 
transport system was investigated, since the compounds may also inhibit the enzyme by 
interfering with the transfer of electrons. 
4.3.1.1  Cytochrome P450 activity assay of partially purified CYP11B1 
Prior to the isolation and purification of substrate-bound CYP11B1, a cytochrome P450 activity 
assay was undertaken to determine both the concentration and the activity of the 
P450-enriched mitochondrial preparation. The results from this assay, depicted in Figure 44, 
show a maximum peak at 450 nm, with a deep trough at approximately 405 nm and a shallow 
trough starting at 480 nm. The P450-enriched mitochondrial preparation was free from P420 
and could therefore be subjected to the next step in the isolation and purification of CYP11B1. 
The cytochrome P450 concentration was calculated to be 2.350 nmol/mg protein. 
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Figure 44. CO-induced difference spectrum of mitochondrial preparation containing CYP11B1. Mitochondrial preparation, 20 mg/mL standard buffer; [P450], 2.350 nmol 
P450/mg protein. 
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4.3.1.2  Elution profile of purified substrate-bound CYP11B1 from ovine 
adrenal  
CYP11B1 was purified by using preparative HIC on a Phenyl-Sepharose column at 4°C. The 
elution profile of purified substrate-bound CYP11B1 is shown is Figure 45. Two peaks (Peak 1 
and Peak 2) were eluted during the chromatographic separation. The fractions constituting 
Peak 1 were eluted with equilibration buffer (standard buffer, supplemented with 0.7 % sodium 
cholate and 200 mM KCl, pH7.4), whereas the fractions constituting Peak 2 were eluted with 
elution buffer (standard buffer, supplemented with 0.5% sodium cholate, 500 mM KCl and 
0.5% Tween20, pH 7.4).  
To determine whether the fractions from Peak 1 and 2 contained active CYP11B1, a 
cytochrome P450 activity assay was performed for each fraction from Peak 1 and 2. As shown 
in Figure 46 Peak 1 contained only P420. This indicated that the CYP11B1 in this fraction 
was converted to its inactive form and no further studies could be performed using these 
fractions. The fractions constituting Peak 2, shown in Figure 47, had a maximum absorbance 
at 450 nm, indicating that these fractions contained active, substrate-bound CYP11B1. 
Fraction 13 and 14, however, had a small trough at 420 nm, therefore to preserve activity, 
Fractions 13 and 14 were excluded from further purification procedures, whereas fraction 15-
18 were collected and concentrated with ammonium sulphate and dialysed. The CYP11B1 
concentration of the pooled fraction was 8.327 nmol/mg protein.  
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Figure 45. Elution profile of substrate-bound CYP11B1. The dialysed CYP11B1 was applied to an equilibrated Phenyl-Sepharose CL-4B column (8 cm x 1 cm), washed 
with equilibration buffer, and eluted at 1 mL per minute, with an elution buffer. 
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Figure 46. CO-induced difference spectrum of collected Fractions 2-4, (Fig 45 peak 1). The maximum at 420 nm 
represents the inactive form of CYP11B1. 
 
Figure 47. CO-induced difference spectrum of collected Fractions 13-18 (Fig 45 peak 2). The peak at 450 nm 
represents the active form of CYP11B1. The concentration of the pooled chromatographic fractions was 
8.327 nmol/mg protein. 
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4.3.1.3  SDS-PAGE and Western blot analysis of purified CYP11B1 
The purity of CYP11B1 in respective fractions eluted from Peak 1 and Peak 2 was analysed 
using SDS-PAGE analysis. As shown in Figure 48 A, Lanes 2, 3 and 4 represent a 10 x 
dilution of Fractions 2 (20 µg protein), 3 (25 µg protein) and 4 (7.5 µg protein) collected from 
Peak 1, while lanes 5, 6 and 7, contain Fractions 16 (15 µg protein), 17 (13 µg protein),18 (10 
µg protein) collected from Peak 2. Lane 8, represents the pooled fractions 15-18 collected 
from Peak 2 (18 µg protein), depicting the apparent molecular mass of substrate-bound 
CYP11B1, as previously reported in our laboratory (18). A 30 x dilution (12.30 µg protein) of 
the crude CYP11B1 preparation prior to HIC, was used as a positive control (Lane 9).  
SDS-PAGE analysis revealed that the Phenyl-Sepharose resin successfully separated 
CYP11B1 from the other mitochondrial proteins, as a single protein band at approximately 
46 kDa is shown in Lane 5-8. The protein bands in Lane 2, 3, 4 and 9 indicate the presence 
of the larger CYP11A1 protein, CYP11B1, CYP11B2, as well as ADX and ADXR.  
Although the mitochondrial preparation had been subjected to ultra-centrifugation, with the 
mitochondrial proteins (CYP11A1, CYP11B1 and CYP11B2) remaining in the pellet and the 
redox proteins (ADX and ADXR) in the supernatant, it is possible that the redox proteins bound 
to the mitochondrial proteins’ sediment in the pellet. Therefore, it is possible that the feint band 
visible in Lane 5-8 at ±10 kDa may be residual ADX bound to the enzyme, with the enzyme 
freed from its redox partner under the denaturing electrophoreses conditions. 
A duplicate gel was subjected to Western blot analysis and probed using rabbit anti-sheep 
CYP11B1 IgG against as primary anti-body and goat anti-rabbit IgG as the secondary anti-
body. The immunoblot results are shown in Figure 48 B. The antibodies recognised a single 
band in lanes representing Fractions 16, 17, 18 and the pooled chromatographic fractions. 
The purity of CYP11B1 from ovine adrenals was thus confirmed by SDS-PAGE and Western 
blot analyses. 
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Figure 48. (A) SDS-PAGE analysis of purified-substrate bound CYP11B1 with apparent molecular mass of 46 kDa. 
Column eluate samples were separated on a 12% gel. Lane 1: Precision Plus Protein™ Kaleidoscope™ marker 
(10-250 kDa); Lane 2, fraction 2, 10 x dilution 20 µg protein; Lane 3, fraction 3, 10 x dilution 25 µg protein; Lane 4, 
Fraction 4, 10 x dilution 7.5 µg protein; Lane 5, Fraction 16, 15 µg protein; Lane 6, Fraction 17, 13 µg protein; Lane 7, 
Fraction 18, 10 µg protein; Lane 8, pooled chromatographic fractions of 2nd elution peak, 18 µg protein; and Lane 9 
partially purified extract, 30 x dilution 12.30 µg protein. (B) Western blot analysis of purified substrate-bound CYP11B1. 
Lanes 1 – 3, fractions 16, 17 and 18; and Lane 4 pooled chromatographic fractions of 2nd elution peak. CYP11B1 was 
detected with rabbit anti-sheep IgG against CYP11B1 (1:4000) and goat anti-rabbit IgG (1:20 000) was used as the 
secondary antibody. Immunoblot bands were visualised by chemiluminescence.  
 
A. 
B. 
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4.3.1.4  Degree of purity of substrate-bound CYP11B1 
The degree of purity of the substrate-bound CYP11B1 was determined spectrophotometrically 
by performing a cytochrome P450 activity assay as well as a protein determination after each 
major purification step (Table 6). 
Table 6. Purification table for CYP11B1 isolated from ovine adrenals 
Purification step 
Volume 
(mL) 
Protein 
(mg) 
Total 
CYP11B1 
(nmol) 
Specific 
activity 
(nmol/mg) 
Purification 
factor 
Yield 
(%) 
Crude extract 118 2376.92 5585.77 2.350 1.00 100 
Ammonium sulphate 
precipitate fraction 
105 980.50 3730.33 3.805 1.62 66.78 
HIC chromatography on a 
Phenyl-Sepharose 
column 
20 122.56 1020.60 8.327 3.54 18.27 
CYP11B1-reconcentrate 
with ammonium sulphate 
5 16.80 194.26 11.563 4.92 3.48 
 
CYP11B1 was successfully purified using preparative HIC on a Phenyl-Sepharose CL-4B 
resin. The purity of CYP11B1 was increased 5-fold, which was comparable with results 
previously reported by our laboratory (18). Loss of enzyme activity was, however, seen after 
the chromatography step, which can be attributed to the incomplete precipitation after the 
dialysis step. The final concentration of substrate-bound CYP11B1 was 11.56 nmol/mg 
protein. 
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4.3.1.5  Cytochrome P450 activity assay of substrate-free CYP11B1 
A cytochrome P450 activity assay was carried out before DOC- or inhibitor-induced difference 
spectra were performed to establish whether the purified substrate-free enzyme had remained 
active after the removal of the stabilizing substrate. The result of this cytochrome P450 activity 
assay is illustrated in Figure 49. 
A cytochrome P450 activity assay was performed immediately after the filtration process, 
which is shown in black. A maximum peak at 450 nm was observed with a shallow trough at 
480 nm indicating that the substrate-free CYP11B1 was active. The cytochrome P450 
concentration of the substrate-free CYP11B1 immediately after the filtration process was 
10.950 nmol/mg protein. 
To establish the rate of CYP11B1 decay, the enzyme activity was monitored at 5 minute 
intervals. After 45 minutes a maximum peak at 420 nm was seen, with a small peak visible at 
450 nm indicating a ± 90% conversion to inactive P420.  
 
 
 
 
 
 
  
Figure 49. CO-induced difference spectrum of reduced purified substrate-free CYP11B1 in standard buffer. 
[CYP11B1] = 10.950 nmol P450/mg protein; black trace, CYP11B1 immediately after the filtration process; red trace; 
CYP11B1 after a 45 minutes;  
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4.3.1.6  Spectral assays with substrate-free CYP11B1 
CYP11B1 was extremely labile when released from DOC, as seen in Figure 49. Loss of 
enzyme activity was therefore expected and thus only a limited time was available to perform 
spectral assays. Furthermore, due to the total amount of purified enzyme (5 mL) available, 
careful planning was key to the successful recording of the DOC-induced difference spectra.  
4.3.1.6.1 DOC/inhibitor-induced difference spectra with substrate-free CYP11B1 
The difference spectra were performed in duplicate by the 96-well micro-titre plate assay and 
data presented as the mathematical mean. The influence of the racemic mixture of CpDA, and 
the R- and S-enantiomers of CpDA on the DOC-induced difference spectrum of purified 
CYP11B1 is shown in Figure 50, Figure 51 and Figure 52, respectively. 
As described in Chapter 3, CpDA, at a concentration of 750 µM, inhibited the DOC-induced 
difference spectra of CYP11B1 by ± 50%. The same concentration of inhibitor was therefore 
used as a standard for all substrate-induced difference spectra of purified CYP11B1.  
As shown in Figure 50 A, the amplitude of the DOC-induced difference spectrum of purified 
CYP11B1 was reduced significantly with CpDA inhibition of the difference spectrum being 
52.30 %. Additionally, when CpDA was added to the enzyme in the absence of DOC, a typical 
Type II difference spectrum was induced, with an absorbance maximum at 430 nm and 
absorbance minimum at 412 nm (Figure 50 B). These results corroborated previous studies 
which showed that CpDA binds to the active site of CYP11B1 and inhibits the binding of DOC 
to the enzyme. Furthermore, CpDA (200 µM) was shown to have the ability to induce a Type II 
difference spectrum as it stabilizes the low-spin state of the iron (27).  
In the presence of the R-enantiomer, the amplitude of the DOC-induced difference spectrum 
was also reduced but to a lesser degree compare to the reduction by CpDA (Figure 51 A). 
The R-enantiomer inhibited DOC binding by 14.90%, indicating that the R-enantiomer was 
± 3.5-fold less effective than racemic CpDA. Furthermore, the addition of the R-enantiomer 
(200 µM) in the absence of DOC to CYP11B1 induced a Type II difference spectrum, with a 
maximum and minimum at 430 and 412 nm, respectively (Figure 51 B). The Type II spectrum 
induced by the R-enantiomer had a similar Type II profile as the spectrum induced by CpDA. 
Under the same conditions, the S-enantiomer inhibited the DOC-induced difference spectrum 
by 35.18% (Figure 52 A). The S-enantiomer was 1.5-fold less effective than the racemic 
mixture of CpDA. Interestingly, the inhibitory effect of both the R- and S-enantiomers combined 
was 50.08%, which is equivalent to the percentage inhibition induced by the racemic mixture 
of CpDA (52.30%). In a paper by Mentel et al. (94) they describe three modes for enantiomers 
of a chiral compound to bind the active site of a protein: the protein is selective for one 
Stellenbosch University  https://scholar.sun.ac.za
 
 
88 
 
enantiomer in a racemic mixture, the R-and S-enantiomers can bind to the protein individually 
and both enantiomers can bind to the active site of the protein, simultaneously. This result 
obtained from the spectral assays could possibly mean that the inhibitory effect induced by 
the racemic mixture of CpDA could be due to both the enantiomers binding to the active site 
simultaneously. 
Furthermore, when the S-enantiomer (200 µM) was added to CYP11B1 in the absence of 
DOC, a Type II difference spectrum was induced (Figure 52 B). However, the S-enantiomer 
induced a distorted Type II profile when compared to CpDA and the R-enantiomer, as two 
maxima were observed at 445 nm and 470 nm and a minimum absorbance at 408 nm, 
respectively. As previously mentioned, CpDA is classified as a mixed inhibitor of ovine 
CYP11B1. CpDA, therefore, has the ability to inhibit the enzyme in a competitive or 
uncompetitive manner (27). The mixed inhibitory effect of CpDA can therefore be attributed to 
manner in which the individual enantiomers bind to the active site of CYP11B1.  
The results obtained from the spectral assays revealed that the inhibitory effect induced by 
the racemic mixture of CpDA is significantly reduced when the enantiomers are separated. 
Furthermore, the results also suggest that the enantiomers bind simultaneously to the active 
site of CYP11B1 from ovine adrenals, however further experimental work is required. 
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Figure 50. (A) Influence of the racemic mixture of CpDA on the DOC-induced difference spectra with purified 
CYP11B1. CpDA, 750 µM, inhibition, 52.30%; [CYP11B1] = 10.950 nmol/mg protein. [DOC] = 10 µM. (B) CpDA-
induced Type II difference spectrum of purified CYP11B1. [CYP11B1] = 10.950 nmol/mg protein. [DOC], 10 µM; 
and [CpDA], 200 µM. 
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Figure 51. (A) Influence of the R-enantiomer of CpDA on the DOC-induced difference spectra with purified CYP11B1. 
R-enantiomer, 750 µM, inhibition, 14.90%; [CYP11B1] = 10.950 nmol/mg protein. [DOC] = 10 µM. (B) R-enantiomer 
of CpDA-induced Type II difference spectrum of purified CYP11B1. [CYP11B1] = 10.950 nmol/mg protein. [DOC], 
10 µM; and [CpDA], 200 µM. 
A. 
 
B. 
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Figure 52. (A) Influence of the S-enantiomer of CpDA on the DOC-induced difference spectra with purified CYP11B1. 
S-enantiomer, 750 µM, inhibition, 35.18%; [CYP11B1] = 10.950 nmol/mg protein. [DOC] = 10 µM. (B) S-enantiomer 
of CpDA-induced Type II difference spectrum of purified CYP11B1. [CYP11B1] = 10.950 nmol/mg protein. [DOC], 
10 µM; and [CpDA], 200 µM. 
 
A. 
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4.3.2  Isolation of the adrenal mitochondrial electron transport chain 
ADX and ADXR were prepared to determine whether the R- and S-enantiomers of CpDA and 
the racemic mixture of CpDA has an effect on the adrenal mitochondrial steroid electron 
transport system. Cytochrome c was used as the terminal electron acceptor and the reduction 
of cytochrome c was monitored spectrophotometrically by a modification of the method 
previously published (14, 90). 
4.3.2.1  SDS PAGE and Western blot analysis of isolated ADXR/ADX  
ADX and ADXR were isolated from partially purified adrenal mitochondria from ovine adrenals 
and concentrated by using PEG 35 000. Both the crude and concentrated ADXR/ADX solution 
were subjected to SDS-PAGE and Western blot analysis. The results obtained in the 
SDS-PAGE analysis (Figure 53 A) show distinct bands in both lanes 2 and 3 at ± 48 kDa and 
10 kDa corresponding to the apparent molecular mass of ADXR and of ADX, respectively. 
Lane 2 represents the crude ADX/ADXR solution, whereas lane 3 represents the concentrated 
ADXR/ADX solution.  
Western blot analysis was carried out to confirm that the distinct bands in the SDS-PAGE gels 
were ADXR and ADX, shown in Figure 53 B and C. Because different primary antibodies 
were required to identify ADXR and ADX, two separate blots were prepared. A single band 
was detected in Lane 1 and 2 using rabbit anti-sheep ADX IgG shown in Figure 53 B, with 
Lane 1 representing the crude ADXR/ADX solution and Lane 2 the concentrated ADXR/ADX 
solution. Shown in Figure 53 C is the second immunoblot in which rabbit anti-sheep ADXR 
IgG was used to detect the ADXR protein band. Lane 1 and 2 of the ADXR blot represents the 
crude ADXR/ADX solution and concentrated ADXR/AXD solution, respectively.  
In both immunoblots, the concentrated ADXR/ADX protein mixture had a more intense signal 
when compared to the crude ADXR/AXD protein, indicating that ADXR and ADX were indeed 
concentrated from the crude solution. The presence of ADXR and ADX was therefore 
confirmed by SDS-PAGE and Western blot analyses. 
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C. 
Figure 53. (A) SDS-PAGE of ADX and ADXR. Lane 1, Kaleidoscope protein marker; Lane 2, crude ADXR/ADX preparation; and Lane 3 concentrated ADXR/ADX preparation. In 
each lane, 20 µg protein was loaded. (B) Western blot analysis of ADX. Lane 1, crude ADXR/ADX preparation and Lane 2, concentrated ADXR/ADX preparation. In each lane, 
20 µg protein was loaded. Rabbit anti-sheep ADX IgG 1:6000. (C) Western blot analysis of ADXR. Lane 1, crude ADXR/ADX preparation and Lane 2, concentrated ADXR/ADX 
preparation. In each lane, 20 µg protein was loaded. Rabbit anti-sheep ADXR IgG, 1:6000; goat anti-rabbit IgG (1:20 000). 
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4.3.2.2  The influence of CpDA and the enantiomers of CpDA on the reduction 
of cytochrome c by the ADX/ADXR electron transport system 
Before the influence of racemic CpDA and the R- and S-enantiomers on the reduction of 
cytochrome c could be determined, the activity of ADX/ADXR needed to be established. The 
activity of the concentrated ADX/ADXR preparation was therefore monitored 
spectrophotometrically at 550 nm and was calculated from the amount of cytochrome c (nmol) 
reduced per second using a millimolar extinction coefficient of reduced cytochrome c, 29.5 
cm-1 mM-1(90). 
After pre-incubation for 5 minutes at 25°C, NADPH was added to both the incubation mixtures 
in the reference well (without ADX/AXR) and sample well (with ADX/ADXR) to initiate the 
reaction. As shown in Figure 54, the red trace represents the sample well and the black trace 
the reference well. In the absence of ADX/ADXR, the reducing equivalents from NADPH could 
not reduce cytochrome c, therefore the absorbance reading remained constant and a straight 
line (black trace) was observed at approximately 0.522 mAU. The red curve clearly indicates 
the increase in the absorbance at 550 nm due to the reduction of cytochrome c. The reduction 
plateaued at ± 60 seconds and at 100 seconds complete reduction of cytochrome c was 
reached as the NADPH concentration was not limiting. The amount of cytochrome c reduced 
was calculated using a millimolar extinction coefficient of 29.5 cm-1 mM-1 and a path length of 
0.60561 cm (90). 
The influence of CpDA, at two concentrations, on the reduction of cytochrome c is shown in 
Figure 55 A. The blue curve represents CpDA at 750 µM and the green curve at 375 µM. 
Data suggested that CpDA inhibited the initial reaction rate when compared to control without 
the compound (red curve).  A plateau is reached after 110 seconds compared to the 100 
seconds in the absence of CpDA. The reduction of cytochrome c was analysed by fitting a 
linear regression model on the linear section of the curve and the results are shown in Figure 
55 B. The initial rate of cytochrome c reduction by the ADXR/ADX preparation without inhibitor 
was 0.01008 nmol/sec (0.01 nmol/sec). In the presence of CpDA (750µM and 375 µM), the 
rate of cytochrome c reduction was 0.007474 nmol/sec (0.0075 nmol/sec) and 0.007915 
nmol/sec (0.008nmol/sec), respectively. As the influence of CpDA on the mitochondrial 
electron transport chain was not directly concentration dependent, it can be assumed that 
CpDA does not have a significant influence on the reduction of cytochrome c via the 
ADX/ADXR electron transport system. 
The influence of the R-enantiomer and the S-enantiomer on the reduction of cytochrome c is 
shown in Figure 56 A and Figure 57 A, respectively. In Figure 56 A, the orange curve 
represents the R-enantiomer at 750 µM and the light-green curve at 375 µM. The purple curve 
Stellenbosch University  https://scholar.sun.ac.za
 
 
95 
 
in Figure 57 A represents the S-enantiomer at 750 µM and the light-blue curve at 375 µM. It 
appears that both the R- and S-enantiomer behave similarly to CpDA, as the respective 
enantiomers also inhibit the initial rate when compared to the control.  In the absence of 
inhibitor, the plateau was reached at 100 seconds while the R- and S-enantiomers of CpDA 
reached a plateau after 110 seconds, comparable to racemic CpDA. 
The reduction of cytochrome c was analysed by fitting a linear regression model on the linear 
section of the curve. The effect of the R- and S-enantiomers on the reduction of cytochrome c 
are shown in Figure 56 B and Figure 57 B, respectively. The initial rate cytochrome c 
reduction by the ADXR/ADX preparation without inhibitor (red-curve) in both Figure 56 B and 
Figure 57 B was 0.01 nmol/sec. In the presence of the R-enantiomer at 750µM and 375 µM, 
the rate of cytochrome c reduction was 0.0077 nmol/sec and 0.0083 nmol/sec respectively 
(Figure 56 B). In the presence of the S-enantiomer, 750µM and 375 µM, the rate of 
cytochrome c reduction was 0.0077 nmol/sec and 0.0084 nmol/sec respectively (Figure 
57 B). As the influence of the R- and S-enantiomers of CpDA on the adrenal mitochondrial 
electron transport chain was not concentration-dependent, it can be assumed that neither the 
R-enantiomer or the S-enantiomer had a significant influence on the reduction of cytochrome 
c by the ADX/ADXR electron transport system. 
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Figure 54. Reduction of cytochrome c by the ADX/ADXR electron transport system. The red curve represents the 
incubation mixture of the sample well (cytochrome c, ADX/ADXR, G6P and G6PD). The black line represents the 
incubation mixture of the reference well without the ADX/ADXR preparation. 
Stellenbosch University  https://scholar.sun.ac.za
 
 
97 
 
 
 
  
 
  
Figure 55. (A) Reduction of cytochrome c by the ADX/ADXR electron transport system. The red curve represents 
the incubation mixture of the sample well (cytochrome c, ADX/ADXR, G6P and G6PD). The black line represents 
the incubation mixture of the reference well without the ADX/ADXR preparation. The blue curve represents the 
incubation mixture with racemic CpDA, 750 µM, and the green curve the incubation mixture with racemic CpDA, 
375 µM. (B) Linear regression of the first 30 seconds of the curves. 
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Figure 56. (A) Reduction of cytochrome c by the ADX/ADXR electron transport system. The red curve represents 
the incubation mixture of the sample well (cytochrome c, ADX/ADXR, G6P and G6PD). The black line represents 
the incubation mixture of the reference well without the ADX/ADXR preparation. The orange curve represents the 
incubation mixture with the R-enantiomer, 750 µM, and the light green curve the incubation mixture with the 
R-enantiomer, 375 µM. (B) Linear regression of the first 30 seconds of the curves. 
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Figure 57. (A) Reduction of cytochrome c by the ADX/ADXR electron transport system. The red curve 
represents the incubation mixture of the sample well (cytochrome c, ADX/ADXR, G6P and G6PD). The black 
line represents the incubation mixture of the reference well without the ADX/ADXR preparation. The purple curve 
represents the incubation mixture with the S-enantiomer, 750 µM, and the light blue curve the incubation mixture 
with the S-enantiomer, 375 µM. (B) Linear regression of the first 30 seconds of the curves. 
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4.4 Conclusion 
This study aimed to investigate the influence of the R- and S-enantiomers of CpDA on the 
spectral properties of CYP11B1 and the adrenal mitochondrial electron transport system. 
In our laboratory CYP11B1 was previously isolated and purified from ovine adrenals using 
preparative HIC on an aniline-Sepharose resin. Aniline-Sepharose is, however, not 
commercially available and has to be prepared by the CNBr activation of Sepharose CL-4B 
followed by the coupling of aniline to the activated Sepharose resin. This procedure involves 
two toxic chemicals, aniline, which has to be distilled prior to use, and CNBr. Due to the toxic 
nature of these substances, a modified method was employed for the purification of CYP11B1, 
which involved replacing the aniline-Sepharose resin with commercially available 
Phenyl-Sepharose CL-4B resin. By employing this modified method, substrate-bound 
CYP11B1 was successfully purified from a P450-enriched mitochondrial powder from ovine 
adrenals, resulting in a ± 5-fold purification, with a recovery yield of 3.5% (Table 6). These 
results were comparable to previous studies in our laboratory (purification fold 5% and 
recovery yield 2.9%) using the aniline-Sepharose resin (18). The substrate, DOC, was used 
to stabilize CYP11B1, however, as membrane-bound enzyme are highly labile when released 
from their membranes, loss of enzyme activity was expected during the purification process. 
The loss of enzyme activity could be attributed to the incomplete precipitation after the dialysis 
steps. From this data it can be concluded than the new resin served as a safer and effective 
alternative to purify CYP11B1. 
It has previously been reported in our laboratory that the molecular weight of CYP11B1 from 
ovine adrenals is 46 kDa (18). SDS-PAGE and Western blot analysis confirmed the presence 
of CYP11B1, with a prominent single band at approximately 46 kDa, as shown in Figure 48 A 
and B. There was, however, a feint protein band visible at ±10 kDa in Lane 5-8 of the 
acrylamide gel, indicating the presence of residual ADX bound to CYP11B1, with the enzyme 
freed from its redox partner under the denaturing electrophoreses conditions. 
DOC stabilises the high spin-state of the heme-iron of CYP11B1 (7, 18, 27). Therefore, before 
any spectral assays could be completed, the conversion of the heme-iron of CYP11B1 back 
into the low-spin state form was a prerequisite. This removal of DOC from substrate-bound 
CYP11B1 was achieved using DCC, to adsorb the steroid, and a combination of filtration and 
centrifugation to separate the steroid from the substrate-free CYP11B1 solution. After the 
removal of DOC, the substrate-free CYP11B1 was extremely unstable and complete loss of 
enzyme activity resulted within one hour (Figure 49).  
Spectral assays were employed using a modified technique, which involved down-scaling from 
1.5 mL quartz cuvettes to a 96-well micro-titre assay. Due to the limited time that the 
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substrate-free enzyme remained active and the amount of purified enzyme available, the 
modified technique served as an effective and efficient means to investigate the mechanism 
of action of the R- and S-enantiomers of CpDA.  
It was previously reported that CpDA inhibits the DOC-induced difference spectrum and also 
induces a Type II difference spectrum in the absence of substrate in CYP11B1 (27). Results 
presented in this chapter (Figure 50 A and B), confirmed these reports. Furthermore, the 
results obtained in the spectral assays have revealed that both the R- and S-enantiomers of 
CpDA also inhibited the DOC-induced difference spectrum of CYP11B1 and induced Type II 
difference spectra (Figure 51 and Figure 52). Interestingly, it was found that separating the 
single enantiomers of CpDA did not increase its inhibitory profile. In fact, the results suggest 
that total inhibitory effect induced by the racemic mixture of CpDA, can be attributed to the 
combined effect of both the R- and the S-enantiomers. Furthermore, it was found that the 
S-enantiomer displayed a completely different or distorted Type II difference spectrum when 
compared to the racemic mixture of CpDA and the R-enantiomer.  
CpDA was previously reported to act as both a competitive and uncompetitive inhibitor, 
suggesting that CpDA can bind in a reversible manner to the active site of CYP11B1 and 
prevent substrate-enzyme complex formation or CpDA can bind to the enzyme-substrate 
complex and cause structural distortion of the active site (27). Previous results have also 
suggested that that enantiomers of a chiral compound can bind simultaneously to the active 
site of an enzyme (94). Results obtained from the spectral assays in this study suggest that 
the R- and S-enantiomer bind simultaneously to CYP11B1 but in different regions of the active 
site of the enzyme to induce an inhibitory response, however further studies would be required 
to confirm this finding. Furthermore, as shown with the purified substrate-free CYP11B1, the 
inhibition of the enzyme by CpDA and the R- and S-enantiomers of CpDA occurs at the 
enzyme-substrate level as the compounds had no significant effect on the electron transport 
system confirmed in the unhindered ADXR/ADX-catalysed reduction of cytochrome c. 
To summarize, whether the initial hypothesis that either the R- or S-enantiomers of CpDA 
could be linked specifically to a more effective inhibitory profile remains uncertain. While the 
S-enantiomer exhibits a greater inhibitory effect on substrate binding than the R-enantiomer, 
their combined inhibition reflects that of CpDA.  It should however be noted that the 
enantiomers were not present at the same concentrations in CpDA with the R- and S- 
enantiomers being present at ±11.5:1 in the racemic mixture of the synthesised compound.  
Given the molar distribution and, together with the fact that the S-enantiomer exhibited a 
greater inhibitory effect on substrate/CYP11B1 binding, it could be concluded that this 
enantiomer may be the more effective compound in terms of both the R-enantiomer as well 
as CpDA. However, future studies are required to confirm this statement.  
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CHAPTER 5 
General discussion 
 
Since the first study conducted with S2, the natural counterpart from the shrub Salsola 
tuberculata in the early 1960s, our understanding of CpDA has advanced substantially. We 
now know that, not only does CpDA interfere with the terminal reaction in the adrenal 
glucocorticoid biosynthesis pathway, but it has also been identified as a non-steroidal multi-
target AR and GR modulator, with the potential to treat various inflammatory and auto-immune 
diseases, as well as certain cancers (30). Because the unique pharmacological properties of 
CpDA allow it to be a prospective candidate to treat various diseases and clinical conditions 
associated with AR and GR signalling, it was important to investigate a method whereby its 
therapeutic range could be improved. Therefore, in an attempt to enhance its pharmacological 
properties and gain further insight into the mechanism of action of CpDA, this study aimed to 
separate the enantiomers of CpDA and elucidate the biochemical mechanism of action of the 
respective enantiomers using the spectroscopic properties of CYP11B1.  
The first aim of this study was to synthesize a racemic mixture of CpDA. This racemic mixture 
was subsequently used to separate the R- and S-enantiomers from the racemate. It also 
served as a standard while investigating the mechanism of action of the respective 
enantiomers. Precautionary steps, such as working in a dark and in an oxygen free 
environment, were taken to preserve its activity during synthesis. LC-Q-ToF/ESI-MS, 1H-NMR 
and 13C-NMR spectroscopy confirmed the successful synthesis of CpDA, while CYP11B1 
spectral assays confirmed biological activity. Impurities present in the racemic mixture of the 
compound could not be completely removed. The yield obtained was, however, considered to 
be sufficient to proceed to the chiral resolution of the R- and S-enantiomers of CpDA.  
Diastereomeric salt crystallisation was chosen to separate the R- and S-enantiomers of CpDA. 
Although other methods for the separation of enantiomers are available, diastereomeric salt 
crystallisation was considered to be the most cost-effective and time efficient method, when 
compared to other separating procedures (48, 49). A modified approach was employed for the 
separation of the enantiomers of CpDA. This approach was inspired by the work of Ault, who 
separated the R- and S-enantiomers of a structurally similar compound, 1-phenylethylamine 
(86). The separation of 1-phenylethylamine was achieved by reacting a racemic mixture of 1-
phenylethylamine with optically pure (R,R)-tartaric acid to produce two diastereomeric salt 
complexes. The (R, R) salt complex and (S, R) salt complex could be separated by selective 
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crystallization from methanol. A similar approach was used to separate the R- and 
S-enantiomers of CpDA, with precautionary steps taken to prevent the breakdown of CpDA. 
The reaction was scaled down approximately 30-fold and the R- and S-enantiomers of CpDA 
were successfully separated in their biologically active form. However, the respective 
enantiomeric preparations contained impurities which was expected as the starting material 
of the racemic mixture of CpDA was not chemically pure. As a ≥ 95% enantiomerically pure 
sample is required for accurate interpretations of the 3D-configuration of the respective 
enantiomers, the optical rotation of the respective enantiomers could not be determined, due 
to the presence of impurities. It was assumed that the enantiomers of CpDA separated in this 
study were correctly denoted as the R- and S-enantiomers since CpDA is structurally related 
to 1-phenylethylamine. The instability of CpDA was further highlighted by LC-Q-ToF/ESI-MS 
analysis. A large portion of the respective enantiomers cyclized into 2-(4-hydroxyphenyl)-1-
methylaziridine and 2-(4-acetoxyphenyl)-1-methylaziridine, suggesting that the separated 
enantiomers are less stable than the racemic mixture and more likely to lose activity under 
standard laboratory conditions. It is interesting to note that attempts to separate the R- and 
S-enantiomers on a preparative-scale resulted in the complete conversion of CpDA to both 
2-(4-hydroxyphenyl)-1-methylaziridine and 2-(4-acetoxyphenyl)-1-methylaziridine, with a total 
loss of biological activity. For future studies the micro-separation approach, described in this 
study, would need to be refined and optimized to yield sufficient material for the purification of 
the R- and S-enantiomers to allow for the comprehensive characterization of the respective 
enantiomers. Moreover, if the relevant resources were to become available, it would be 
feasible to explore chiral chromatography as a means of separating the enantiomers of CpDA, 
since this approach enables high quality separation on a preparative scale (49).  
In order to establish the biochemical mechanism of action of the respective enantiomers, the 
influence of the R- and S-enantiomers of CpDA was further investigated using the 
spectroscopic properties of a highly purified substrate-free preparation of ovine CYP11B1. 
Membrane-bound cytochrome P450 enzymes are highly labile and rapidly denature into the 
inactive P420 form when removed from the membrane environment. The presence of even 
trace amounts of P420 is undesirable as it masks the influence of an inhibitor on the 
DOC-induced difference spectrum (7, 18, 27). Nonetheless, previous studies in our laboratory 
have reported on the successful isolation and purification of active CYP11B1 by adding an 
excess amount of DOC substrate to the isolation and purification buffers to stabilize the 
enzyme (18, 92). A modified method was used for the purification of substrate-bound 
CYP11B1, which involved replacing the aniline-Sepharose CL-4B resin with commercially 
available Phenyl-Sepharose CL-4B resin. Substrate-bound CYP11B1 was successfully 
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purified from a partially purified CYP11B1-containing mitochondrial powder from ovine 
adrenals and purification was confirmed with SDS-PAGE and Western blot analyses. 
Analyses of the acrylamide gel clearly showed that the Phenyl-Sepharose resin separated 
CYP11B1 from the other mitochondrial proteins. The bands representing these proteins 
(Figure 48 A, Lane 2, 3 and 9), indicate the presence of the larger CYP11A1 protein, and 
while CYP11B1 and CYP11B2 may be represented as a single band the smaller bands may 
indicate the presence of ADX and ADXR. It would appear that residual ADX and ADXR may 
be present in the sample which could be attributed to that small portion of the redox proteins 
bound to CYP11B1. Although the preparation had been subjected to ultra-centrifugation with 
the redox proteins remaining in the supernatant and the mitochondrial proteins in the pellet, it 
is possible that ADX and ADXR bound to CYP11B1 (as well as CYP11B2 and CYP11A1) 
would sediment in the pellet. It is also possible that the feint band visible in the purified sample 
at ±10 kDa may be residual ADX bound to the enzyme, with the enzyme freed from its redox 
partner under the denaturing electrophoreses conditions.   
An essential part of this study was the removal of DOC from the purified enzyme. This was an 
important step as the substrate stabilized the high spin-state of the heme-iron. The preparation 
of substrate-free CYP11B1 was achieved by methods previously published (13, 18). It is 
important to note that, after an hour, substrate free CYP11B1 lost all activity and was fully 
converted to its inactive form. The classic spectroscopic assays using a double beam 
spectrophotometer and 1.5 mL quartz cuvettes was modified for use to a 96-well micro-titre 
plate due to the limited time available before the substrate-free enzyme loses complete activity 
as well as the limited amount of purified substrate-free CYP11B1 available at any given time. 
This new approach served as an effective means to investigate the biochemical mechanism 
of action of the R- and S-enantiomers of CpDA, as the assay time and the amount of enzyme 
required for the assay were both significantly reduced.  
Difference spectra proved that both the R- and the S-enantiomers of CpDA inhibit the binding 
of DOC to the active site of CYP11B1 and have the ability to induce Type II difference spectra. 
However, compared to CpDA, neither the R-enantiomer nor the S-enantiomer inhibited the 
DOC-induced difference spectrum to the same extent as the racemate of CpDA. In fact, the 
inhibitory effect induced by the racemic mixture of CpDA was equivalent to the sum of the 
inhibitory effects of both the R- and S-enantiomers of CpDA. Furthermore, in comparison to 
the typical Type II difference spectrum, induced by CpDA and the R-enantiomer, the 
S-enantiomer induced a distorted Type II difference spectrum with one minimum and two 
maxima absorbance values. These results suggest that the inhibitory effect induced by CpDA, 
could be attributed to both enantiomers binding simultaneously to CYP11B1, but in different 
regions of the active site. It should however be emphasised that the concentration of the 
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R-enantiomer was approximately 12 x more in the racemic mixture of CpDA than the 
S-enantiomer, suggesting that the S-enantiomer has a greater inhibitory profile than that of 
the R-enantiomer and the racemic mixture of CpDA.  
The investigation into the ADXR/ADX-catalysed reduction of cytochrome c further revealed 
that CpDA and the enantiomers of CpDA had no significant effect on the mitochondrial electron 
transport chain, and that the inhibition induced by CpDA and the respective enantiomers 
impact only at the enzyme-substrate level, and not the mitochondrial electron transport chain.  
The initial hypothesis that either the R- or S-enantiomers of CpDA may yield a more effective 
inhibitory profile still remains uncertain. Therefore, future studies require pure R- and 
S-enantiomers of CpDA to determine aspects such as the absolute chirality of the respective 
enantiomers and the inhibition of the catalytic activity of purified CYP11B1 by the respective 
compounds. This future work, involving the effects on the catalytic activity of the R- and 
S-enantiomers of CpDA, could provide a greater understanding of the biological nature of each 
enantiomer and similarly determine whether the S-enantiomer has a greater inhibitory profile 
than the R-enantiomer in terms of catalytic activity. 
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